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The main part of my PhD work focused on the application of an advanced 
integrated technique, based on the coupling of an atomic force microscope (AFM) 
and a stimulated emission depletion (STED) microscope in the study of amyloid 
fibrils formation. This coupled system allows the acquisition of super-resolution 
fluorescence images, perfectly overlapped with AFM topography. Exploiting the 
extended capability offered by this technique, I highlighted some important 
features on the mechanisms followed by the labeled and unlabeled proteins 
through their aggregation pathway. The results demonstrates that labeled 
molecules are involved only in selected pathways of aggregation, among the 
multiple that are present in the aggregation reaction. 
In a second part of my work, I investigated the process of interaction between 
Alpha-synuclein (α-Syn), the pathological peptide associated to the Parkinson’s 
disease, and model lipid membranes. The aim of this study was to identify 
molecular mechanisms that are indicated as the base of neurodegeneration, not 
only in Parkinson’s disease, but also in a large class of disorders, indicated as 
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Figure 1.3 - Schematic representation of the amyloid aggregation process.  
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deep blue helix of the B chain and the deep red helix of the A chain into extended 
β-strands. The spine of the fibril consists of a dry steric zipper formed by the 
mating of the central two strands from the B-chains of the two insulin molecules, 
plus two outer strands from the A-chains of the two molecules (from ref. 280). (c) 
Surface representation of 3D maps of the four insulin fibril structures. (From left 
10 
 
to right) Structure of the fibril with a pair of protofilaments twisting around each 
other. The four-protofilament compact fibril. The six-protofilament fibril. The 
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Figure 2.1 - Simplified Jablonski energy diagram representing fluorescence. 
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fluorescence to the singlet ground state, So. (Image from Wikimedia Commons) 
Figure 2.2 - Schematic configuration of laser scanning confocal microscope 
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Z-feedback loop. 
Figure 2.5 - (a) Lennard-Jones potential (red curve), describes interactions 
between atoms depending on their distance, d. It results from the sum of two 
contributions, related to attractive and repulsive interactions (Image from 
http://www.uni-leipzig.de).  (b) Simplified scheme of AFM photo-detection system 
(optical path elements are not shown). Cantilever deflection results in a shift in 
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11 
 
Figure 2.6 - AFM imaging modes (modified from ref. 279) 
Figure 2.7 - Schematic representation of a force vs distance curve.   
Figure 2.8 - AFM/STED Schematic representation. The confocal and STED 
images are acquired in reflection, while the AFM probe is reaching the sample 
from above, providing a 3D topographical view at high resolution. 
Figure 3.1 - Schematic representation of Insulin Labeling procedure. In Step 
1 labeling of insulin. The following step are: Step 2, purification; step 3, 
quantification; step 4, final solution of labeled and unlabeled insulin in three dye-
to-protein ratio; step 5, fibrillation process.  
Figure 3.2 - Molecular structure of dimeric insulin at pH 2.0. (a) Ribbon 
structure showing the secondary structural motifs, and (b) space filled 
representation of the same dimer. The length and diameter of the cylinder was 
estimated to be 42 and 22 Å, respectively193. (Image from ref. 130) 
Figure 3.3 - (a) JPK Nanowizard III with Zeiss inverted optical microscope. 
(b) Motorized stage with sample holder. (c) Cantilever holder. (d) Description of 
JPK Nanowizard III. Images modified from http://www.jpk.com.  
Figure 3.4 - AFM cantilever. (a) Rectangular silicon cantilever for 
intermittent contact imaging in air. (b) Silicon tip of cantilever in a. (c) Triangular 
silicon nitride cantilevers for imaging in liquid. (d) Silicon nitride tip of cantilever in 
c. 
Figure 3.5 - Correlative AFM/STED setup (a). NanoWizard II AFM stage and 
head in the inset. (b) Images of the same area can be acquired in different modes. 
The excitation and depletion lasers arrive from below (inverted optical 
microscope). The confocal and STED images are acquired in fluorescence, while 
the AFM probe is reaching the sample from above, providing a 3D topographical 
view at high resolution. 
Figure 3.6 - Direct overlay procedure. Panel a shows the total overlay 
procedure. In the first row of this panel, we show a cartoon of the collected optical 
image with inherent aberrations, AFM and the corrected image (Image modified 
from ref. 191). Second row depicts the direct overlay software, which calibrates the 
pictures and makes a grid automatically. The panel b shows the reflection images 
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µm regions in order to calibrate this area using 9 points, as shown. 
Figure 3.7 - Insulin fibril 1:19 dye-to-protein ratio. AFM (a), Confocal (b) 
and STED (c) were analysed by using the Colocalization function by ImageJ (NIH, 
Bethesda, MD, USA). The ratio of colocalization is the ratio between the number 
of colocalized pixels (white pixels in d and e) and the total number of pixel that 
composed the fibrils in the AFM images. 
Figure 4.1 - Thioflavin T kinetic. Time course aggregation of a 50 μM 
solution of insulin at 60 °C, monitored by ThT fluorescence increase (ThT 100 μM). 
Emission wavelength: range 470-540 nm; excitation wavelength: 450 nm; slit 
width: 1nm. Aliquots of 50 μL of solution were taken away at different time 
processes. The points indicate the aliquots extracted in time and the 
corresponding ThT normalized value. 
Figure 4.2 - AFM images of unlabeled insulin aggregated species sampled 
at different instant of kinetic and desiccated on mica. a: t= 0; b: t= 3 days; c: 4 days; 
d: t = 6 days; e: t= 12 days f: t= 14 days. Scale bars a-f: 2 µm. Z-range 7 nm (a, b, c), 
15nm (d, e, f). 
Figure 4.3 - AFM image of mature insulin fibrils. (a) Overview of preformed 
insulin in water diluted 100 times (scale bar: 500 nm). (b) Details of structure (scale 
bar: 200 nm) and (c) relative profile. (Z-range: 15 nm). 
Figure 4.4 - ATTO 488-Insulin 1:19 dye-to-protein ratio aggregated by AFM. 
The images sampled at different instant of kinetic: (a) 0 day, (b) 6 days, (c) 12 days 
(d) 14 days. Scale bar: 2 µm. Z-range: 7 nm (a, b), 15 nm (c, d). 
Figure 4.5 - Insulin aggregation in three dye-to-protein ratios. AFM images 
performed after 10 days incubation in denaturing conditions. (a) 1:19, (b) 1:99, (c) 
1:499. Scale bar: 1 µm. Z-range: 10 nm. 
Figure 4.6 - AFM image of mature insulin fibrils labeled 1:19. (a) Overview 
of preformed insulin in water diluted 100 times (scale bar: 1 µm). (b) Details of 
structure (scale bar: 200 nm) and (c) relative profile. (Z-range: 10 nm). 
Figure 4.7 - The lateral broadening effect led by the tip size. (a) AFM image 
in dry condition of insulin fibrils structure (Scale bar: 100 nm. Z-range: 10 nm). (b) 
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The profile cross-section indicate a height of 4 nm and a length of 30 nm. (c) 
Schematization of broadening effect in AFM image due to tip size effect. 
Figure 4.8 - Correlative technique on amyloid fibrils from bovine insulin in 
1:19 dye-to-protein ratio. The STED and Confocal images are overlaid with AFM 
topography. Scale bar: 1 µm. 
Figure 4.9 - ATTO 488-Insulin fibrils 1:19 images. AFM (a, c), STED 
microscopy (b, d) and the correlative images obtained by c and d (e). The ratio of 
colocalization in this particular field of view is indicated by the histogram (inset e). 
Scale bars: (a, b) 5 µm, (c-e) 2 µm. Z-range: (a, c) 5 nm. 
Figure 4.10 - Detail of insulin 1:19 fibrils in AFM (a), STED (b), Confocal (c). 
(d) AFM profile comparison of the same fibril displayed a not continuous 
distribution of fluorophore. Optical microscope scale bar 2 µm. 
Figure 4.11 - Insulin fibrils obtained from 1:99 (a-c), and 1:499 (d-f) dye-to-
protein ratio.  AFM images (a, d), STED microscopy images (b, e) and correlative 
images obtained by the previous (c, f). Several fibrils are totally unlabeled. This 
result resembles the one obtained at a dye to protein ratio of 1:19. The ratio of 
colocalization is shown by the blue bar in the inset histograms. Scale bar: 1 µm. Z-
range: (a, d) 10 nm. 
Figure 4.12 - ThT fluorescence intensity kinetics of Aβ. Time course 
aggregation of a 25 μM solution of Aβ1-40 (a) and Aβ1-42 (b), monitored by ThT 
fluorescence increase (ThT concentration was 50 μM). Emission wavelength: 482 
nm; excitation wavelength: 450 nm; slit width: 1nm.  
Figure 4.13 - AFM images of amyloid-β peptides just after resuspension of 
the lyophilized peptide in the aggregation medium. Aβ1-42 (a) unlabeled, (b) 1:19, 
(c) 1:99, (d) 1:499. Aβ1-40 (e) unlabeled and (f) 1:19. Scale bar: 1 μm. Z-range: 10 
nm. Insets scale bar: 200 nm. Prefibrillar aggregates are not present at the 
beginning of the aggregation process.   
 Figure 4.14 - Amyloid β fibrils. AFM was used to follow the aggregation of 
Aβ1-42 and to characterize the morphology of the fibrils. (a) Unlabeled, (b) 1:19, (c) 
1:99, (d) 1:499. Aβ1-40 (e) unlabeled and (f) 1:19. Scale bar: 1 µm. Z-range: (a) 10 
nm, (b, c, d, e, f) 20nm.  
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Figure 4.15 - Amyloid aggregates from HF488 Aβ1-42. Different 
concentrations of fluorescent peptides were present. The dye to protein ratios are 
(a-c) 1:19, (d-f) 1:99, (g-I) 1:499. Also at the higher dye-to-protein ratio (a-c) some 
fibrils were not displayed by fluorescence images (e.g., see the withe arrows). 
Scale bar 2 μm. Z-Range (a, g) 10 nm, (d) 5 nm. Overlay graph on the right. 
Figure 4.16 - AFM/STED on HF488 Aβ1-40 aggregates. Fibril imaged by AFM 
(a) and STED (b). The overlapped image (c) in which the green color represent STED 
fibrils, red color AFM fibrils and in white color the ratio of co-localization. The dye 
to protein ratio is 1:19. Scale bar 2 μm. Z-Range (a) 10 nm.  
Figure 4.17 - Amyloid aggregates formed from Aβ1-42 in the absence of 
fluorescent monomers and subsequently labeled via indirect immunolabeling. All 
the features displayed in the AFM images (a, d) are also visible in the STED images 
(b, e) and are colocalized (c, f). Interestingly, the fibrils size, measured by AFM, is 
larger with respect to the unlabeled fibrils, confirming the presence of a large 
amount of antibody on the fibrillar aggregates. Scale bar (a-c) 2 µm, (d-f) 1 µm. Z-
range (a, b) 30 nm. Inset (f) graph of colocalization. 
Figure 4.18 - A stochastic aggregation of the labeled/unlabeled peptides 
should bring to the formation of uniformly labeled fibrils. Our experiments 
indicate a different scenario where just a fraction of the fibrils has a labeled 
component. Other fibrils, dark in the STED analysis, are unlabeled. These two 
products are the results of different aggregation pathways. The correlative 
technique here employed gives an answer to the above question. 
Figure 5.1 - Schematic representation of plasma membrane.  
Figure 5.2 - Phase separation in a supported lipid bilayer containing DOPC, 
Sphingomyelin (SM), Cholesterol and GM1 imaged using AFM. (a) Typical 
morphology. Scale bar: 1 µm. (b) Cross section was taken along the white line in a 
(X-axis). The difference in height between the two phases is   ̴ 2.2 nm. Images and 
plot profile from Oropesa et al.78. (c) Particular view of lipid lα and lo domains. Scale 
bar: 200 nm 
Figure 5.3 - Electron microscopy image of prefibrillar aggregates. The 
images refer to the α-syn mutant (A53T) aggregation, involved in Parkinson’s 
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disease. In the first stage of aggregation the protein shows a characteristic pore-
like structure290. The images show an area of 30.5x30.5 nm. 
Figure 5.4 - Primary and secondary structure of α-syn. To right shows the 
three main domains of α-syn. The N-terminal is an amphipathic domain that 
contains the three point mutations (white bars) linked to the autosomal dominant 
form of PD. The central region is a highly hydrophobic domain that was originally 
identified in patients with AD or LBD, which is the precursor of the non-
amyloidogenic component of the extracellular senile plaque (NAC), which 
promotes the protein aggregation. The C-terminal domain has an acidic character, 
which possesses anti-amyloidogenic properties. 
Figure 5.5 - Schematic representation of the vesicle fusion protocol 
employed in this work. 
Figure 5.6 - Difference in thickness between outer (a) and inner (b) leaflet. 
Figure 5.7 - AFM images of SLB sampled before (a-c) and after 
administration of α-syn aggregates solutions (d-f). After 10 min incubation, α-syn 
induce destabilization on the defected-free bilayer. Scale bar 2 µm (a, d), 500 nm 
(b, e) and 200 nm (c, f). Z-range 10nm. 
Figure 5.8 - The neural inner plasmatic model membrane 
(DOPC/DOPE/SM/POPS/ch) by AFM. The profile section (with the dark line) below 
the image shows the roughness in the initial stage of the scan session.  Scale bar 1 
µm (a, b), 500 nm (c). Z-range 6 nm (a, b), 10 nm (c). 
Figure 5.9 - AFM Images of α-syn interaction with 
DOPC/DOPE/SM/POPS/ch bilayer. After 10 min incubation time oligomers peptide 
induced removal of bilayer parts and consequent holes formation. (a) 20 nM and 
(b) 70 nM concentration of α-syn deposited. The black line indicates a profile 










The main aim of my PhD was to apply a new and original approach in the 
study of misfolded protein aggregation, a phenomenon related to several diseases 
(e.g., Alzheimer's and Parkinson's diseases). In particular, I investigated the 
morphological properties of amyloid fibrils derived by a mixture of labeled and 
unlabeled peptides by applying an advanced integrated system obtained from the 
coupling of a standard atomic force microscope (AFM) and a super-resolution 
optical microscope. This approach is new in the field of misfolded protein 
aggregation. 
In the first chapter of this thesis, I introduce amyloid proteins and related 
diseases, i.e. amyloidosis. Chapter 2 gives an overview on the microscopy 
techniques employed (super-resolution fluorescence microscopy and Atomic 
Force Microscopy, AFM). 
In Chapter 3, the different experimental approaches and methods 
employed in this thesis are reported. A focus on the results obtained by means of 
correlative AFM-STED microscopy on the aggregation of insulin and two isoform 
od Amyloid-β peptides have been reported in Chapter 4. 
 In parallel I carried out a second activity aims to define the molecular 
mechanism at the base of the interaction between a pathological petide, α-Syn, 
and lipid membranes. In particular, since α-Syn is present in both the cytosolic and 
the extracellular environment, I examined the interaction between this peptide 
and artificial lipid membranes that mimic the composition of both the internal and 
the external leaflets of the cell membrane. In Chapter 5, I present results related, 
obtained by AFM technique, investigating the process of interaction between α-





Chapter 1  
 Amyloid diseases 
 
A wide range of human diseases, including Alzheimer's and Parkinson's 
disease, Spongiform Encephalopathies, systemic amyloidosis and type II diabetes 
is characterised by uncorrected self-assembly and deposition of proteins material 
commonly called amyloid fibrils1,2. In each of these disease states, peptide passes 
from its soluble and functional form into an insoluble fibrillar species that 
deposited and accumulated in the body tissue, displaying a specific tinctorial 
affinity for Congo red and Thioflavin T (ThT)3. These peculiar chemical identities of 
the amyloid fibril-forming protein allowed the clinical classification of the 
amyloidosis; some human amyloid-related disorders have been reported in Table 
1.14.  
The term amyloid was employed by the German physician scientist 
Rudolph Virchow in 1854 to describe the cerebral corpora amylacea stained with 
iodine-sulfuric acid5. It was originally thought that amyloid was cellulose by nature 
(from the old Greek amylon=starch). However, it was Friedreich and Kekulé who 
dissected the amyloid-rich segments from the spleen of a patient with 
amyloidosis. In contrast to Virchow, they performed direct chemical analysis of the 
material extracted and reached the definitive conclusion that the main substance 
was protein6.  
During the 19th and early 20th centuries, investigations on the nature of 
amyloid evolved from the macroscopic observations of the tissues to the study of 
amyloid structure. The availability of light microscope technology and 
histopathologic dyes (ThT and Congo red) highly specific, led on to conclude that 
amyloid was structurally amorphous7. Cohen and Calkins in 1959 started electron 
microscopic studies of diverse origins, humans and animals, amyloid tissues 







Today, amyloid is known to have the same core structure, a network of 
polymeric unbranched fibrils resulting from ordered polymerization of specific 
proteins9. 
The diseases characterized by the formation and deposition of amyloid 
fibrils, are generally defined as protein misfolding diseases, that include some of 
the more well-known neurodegenerative pathologies, such as Alzheimer’s and 
Parkinson’s diseases. In this context are included also nonneuropathic localized 
amyloidosis, relates to a group of diseases where aggregation occurs in a single 
Table 1.1 | A summary of the main Amyloid diseases and components of their 
associated fibrillary deposits. (Data from ref. 4) 
clinical syndrome fibril component
Alzheimer’s disease
Aβ peptides (wild-type or mutant); Tau (wild-
type or mutant)
spongiform encephalopathies prion protein (full-length or fragments)
Parkinson’s disease α-synuclein (wild type or mutant)
fronto-temporal dementia Tau (wild type or mutant)
amyotrophic lateral sclerosis superoxide dismutase (wild type or mutant)
Huntington disease huntingtin (polyQ expansion)
cerebellar ataxias ataxins (polyQ expansion)
Spinocerebellar ataxia 17 TATA-boxbinding protein (polyQ expansion)
dentatorubro-pallido-luysian atrophy atrophin 1 (polyQ expansion)
Kennedy disease androgen receptor (polyQ expansion)
familial British dementia ABri peptide
familial Danish dementia ADan peptide
primary systemic amyloidosis Ig light chains (full-length or fragments)
secondary systemic amyloidosis serum amyloid A (fragments)
familial Mediterranean fever serum amyloid A (fragments)
familial amyloid polyneuropathy (FAP)
familial amyloid polyneuropathy (FAP)
senile systemic amyloidosis transthyretin (wild type or fragments thereof)
Finnish hereditary systemic amyloidosis gelsolin (fragments of the mutant protein)
hemodialysis-related amyloidosis (DRA) β2-microglobulin
familial non-neuropathic systemic 
amyloidosis
lysozyme (mutant)
type II diabetes pro-islet amyloid polypeptide (fragments)
hereditary cerebral haemorrhage with 
amyloidosis
cystatin-C (minus a 10-residue fragment); Aβ 
peptides
Inclusion-body myositis (IBM) Aβ peptide
Injection-localized amyloidosis Insulin




type of tissue other than the brain and nonneuropathic systemic amyloidosis 
relates to diseases in which aggregation occurs in multiple tissues.  
Some of these conditions, such as Alzheimer and Parkinson’s diseases, are 
predominantly sporadic, although hereditary forms are well documented. Other 
conditions can arise from specific mutations and are hereditary, e.g. the lysozyme 
and fibrinogen amyloidosis. In addition, the 85% of the amyloid diseases are 
sporadic amyloidosis, and the 10% a hereditary forms, while the 5% can also be 
transmissible in humans, as well as in other mammals, defined spongiform 
encephalopathies10. 
 
1.1 Protein folding and misfolding  
The proteins, synthesized on ribosomes as linear chains of amino acids in a 
specific order following the DNA information encoded, attain own specific 
function through the folding process11. The folding path is the way in which the 
random coiled proteins reach the native structure in the conformational space 
which is characteristic for each biological molecules2. This polypeptide self-
organization is a crucial event occurred after or during the translational process in 
the cytoplasm or specific compartments, such as mitochondria or the endoplasmic 
reticulum (ER) of the cells12. In the last 50 years, many theoretical and 
experimental works have been combined to explain protein folding dynamics, 
defining the so-called  ‘from sequence to folding structure’ dogma13. How this 
process occurs is one of the most complicated and fascinating problems in the 
study of molecular biology: passing from the Levinthal’s paradox (the apparent 
contradiction between the number of possible conformations and the actual 
rapidity by which the protein chain assume its stable conformation - less than a 
second), to a new ‘folding funnel’ view, in which only a small number, energetically 
favorable, of all possible conformations, need to be sampled during its 
transition14–17. The code for the folding process of a random polymer into these 
well-defined structures is overall contained within the sequence of amino acids in 
a polypeptide chain (primary structure)18. The primary stabilizations, that are 
achieved in nearly every native protein, are the ‘secondary’ structure, i.e. the beta 
turns and omega loops along with helices and the sheets, obtained by means of 
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the hydrogen bonding between the amide and carbonyl groups of the main chain 
and several other non-covalent interactions, electrostatic interactions, Van der 
Waals forces, and hydrophobic interactions. 
 
The relationship between the sequence and the fold in polypeptides and 
the rapidity in which the folding process enables the correct structure to be found 
for any given sequence represents a clear example of biological complexity, the 
‘protein-folding problem’19. Inside this regards, the cells exhibit a complex 
regulatory system to promote a biological functional conformation for the 
proteins20 (Figure 1.1). The molecular machinery complex consists of molecular 
Figure 2.1 | Regulation pathways of protein folding in the ER. The synthesized 
proteins, by ribosome, are translocated into the ER, where, with the help of a series of 
molecular chaperones and folding catalysts (not shown), they fold into their three-
dimensional structures. Correctly folded proteins are then transported to the Golgi 
complex and then delivered to the extracellular environment. However, the incorrectly 
folded proteins in which they are ubiquitinated and then degraded in the cytoplasm by 




chaperones, to favor folding of polypeptide chains (both in the cytosol and in the 
endoplasmic reticulum) and the ubiquitin-proteasome pathway, to promote their 
degradation when the three-dimensional correct structure is not achieved21. 
However, despite the incredible organization of cells and intrinsic ability of 
evolved protein sequences to avoid unfolding/misfolding nevertheless occur, 
resulting in either to protein misfunction or to the accumulation of protein 
aggregates22,23. In a crowded cellular environment, surrounded by interacting 
proteins, nascent polypeptides face a formidable challenge in finding the correct 
interactions that result in a folded and functional protein. Such events can be 
associated with changing in environmental conditions, such as pH or temperature, 
misprocessing phenomena chemical modification, aberrant interactions with 
metal ions or moreover from specific mutations in the sequence9,24. However, 
several proteins become trapped in meta-stable intermediate structures which 
are usually recognised by proteasomal machinery and degraded or refolded by 
chaperones25. Alternatively, they can also misfold and self-associate leading to 
formation of either amorphous compounds or structures of elongated ordered 
morphology, known as amyloid fibrils. Most frequently it was found that this 
amyloid aggregation occur through the formation of multiple kinetic 
intermediates. In this scenario, it has been suggested that the generic amyloid 
state may constitute a deep and sharp energetic minimum representing the most 
stable state that multiprotein systems can adopt2,26–28. An accumulation of these 
fibrils can result in a range of human diseases commonly referred to as 
amyloidosis.  
 
1.2 Amyloid structure and aggregation process 
Regardless of the protein structure from which they originate, amyloid 
fibrils show many shared properties, including the peculiar structure, as 
determined in detail using experimental techniques. A typical cross-β super-
secondary structure, in parallel or anti-parallel way, models the core structure of 
each filaments whose strands are perpendicular to fibril axis29–31. Cross-β 
structures results in a peculiar X-ray diffraction pattern where typical inter-sheets 
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and inter-strand distances, are evident resulting  respectively 11 Å and 4.8 Å 32,33 
(Figure 1.2 a).  
The structure is made particularly stable by the presence of an highly 
organized non-covalently bonds originating from a protofilament backbone 
consisting of β-sheet  conformation27,34.  
A typical fibril consists of two to seven proto-filaments, twisted around 
each other to form supercoiled rope-like structures , with an average diameter of 
4–10 nm determined through AFM and electron microscopy (EM) 
measurements35,36. 
The fibril architecture of a number of peptides, including Amyloid β1-40 and 
Amyloid β1-42, have been proposed using constraints obtained from solid-state 
NMR37, and are also consistent with molecular dynamics simulations38. In addition, 
advances in micro-crystallographic techniques enabled the discovery of a high-
resolution structure of a peptide extracted from N-terminal segments of Sup35 
and many others species, reported by Eisenberg’s group39. Their studies have 
confirmed that many peptides, which are unrelated by sequence, adopt the 
characteristic cross-β pattern in the fibril state. The spine of the amyloid fibril 
contains dry steric zippers structure formed from self-complementary40 
sequences suggesting a common structural features, shared by amyloid diseases, 
at the molecular level8,41.  
Real-time monitoring of fibril growth is made possible by highly specific 
probe, such as ThT, a commonly used dye to diagnose amyloid fibrils, both ex vivo 
and in vitro42,43. The benzothiazole dye ThT exhibits fluorescence quantum yield 
enhancement upon intercalation into the cross-β super-secondary structure 
Figure 1.2 | (a) X-ray fibril diffraction pattern of insulin fibrils and (b) EM (from 
ref. 32). (c) AFM image of insulin fibrils desiccated on mica. Scale bar: 200 nm.  
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because of the rotational immobilization of the central C–C bond connecting the 
benzothiazole and aniline rings44–47. Upon the binding, the dye changes its 
absorption/emission spectrum from 385 nm (free dye absorption) / 445 nm (free 
dye emission) to 450 nm / 482 nm33,48,49. Since fluorescence intensity variation, in 
first approximation, appears to depend on the presence of molecule in amyloid 
state and not on the interaction with monomeric or dimeric peptides, fluorescence 
signal at the new emission wavelength is a direct measurement of fibril formation. 
The mechanism by which amyloid fibrils are formed seems to resemble the 
process of crystallization or ordered aggregation of proteins, i.e. a nucleation-
polymerisation process, in which the amyloid growth proceeds through several 
steps50,51 (Figure 1.3).  
This mechanism has been proposed for many of the proteins responsible 
for amyloidosis, first of all the Alzheimer Aβ peptide and the prionic protein52.  
The input to follow this partially unfolding/refolding way come from 
destabilized native conformations53 via mutations or denaturing conditions such 
as non-native pH values54 and elevated temperatures55. In particular several 
studies indicate that during the microscopic processes, the intermolecular 
Figure 1.3 | Schematic representation of the amyloid aggregation process. 
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hydrophobic interactions display a significant role as the determinants of the 
formation rate of the misfolded monomers into different types of oligomers56,57. 
At the onset of the fibrillation process, early aggregates are distinguished as an 
oligomeric protein with a diameter of 2.5–5.0 nm, as confirmed by AFM studies58. 
The formation of amyloid fibrils is not the only pathogenic form of amyloid 
deposition; these species follow different possible pathways. They frequently 
associate with each other into bead-like chains or small annular rings, acting as 
precursors for the formation of extremely organized amyloids such as longer 
protofilaments and eventually generating mature fibrils. During the elongation 
step, the presence of fibrillar templates promotes the quick incorporation of 
amyloidogenic monomers, amyloid complete structure start forming, and the 
kinetics turns out to be fast59. This cooperative phase is followed by a plateau. 
Amyloid aggregates corresponding to each phase of the kinetics can be 
characterized using different techniques, including AFM60.  
 
1.3 Alzheimer’s disease and related protein 
Alzheimer’s disease (AD) is the most frequent neurodegenerative disease 
and the most common cause of dementia in humans, with an estimated 
prevalence of one in nine people over age 65 and of more than one in three people 
over age 8561. Clinically, initial symptom of AD is impaired short-term memory that 
changes to profound memory failure and impairment of cognitive functions, 
consequently neuronal degeneration and death. Despite the remarkable 
improvements in understanding of the pathogenesis of the disease have been 
made over last several decades, the accurate mechanism of AD remains unclear. 
Nowadays the argument about a potential therapeutic strategy is still open62. 
AD neuropathology exhibits two hallmark features: senile plaques 
containing depositions of Amyloid β (Aβ) proteins and neurofibrillary tangles 
(NFT), deriving from hyperphosphorylation of microtubule-associated Tau 
proteins in neurons63. Since the discovery by psychiatrist and pathologist Alois 
Alzheimer in 1906, several theories have been formulated to explain the 
pathogenesis of AD62,64. The central hypothesis for the cause of AD is the failure of 
the protective degradative mechanism of the cells leading to the accumulation of 
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toxic concentrations of Aβ, which aggregates, into plaques thus causing neuronal 
degeneration and consequently leading to dementia - the amyloid cascade 
hypothesis65,66. The high heterogeneity and polymorphisms of amyloid 
aggregates, lead different path of cytotoxicity resulting from several cellular 
mechanisms in which they are involved, specific for every aggregation state. For 
example it has been shown that, in the AD, the presence of Aβ1-42 small oligomers 
impair long-term potentiation67 and raise ER stress68; whereas the presence of the 
major fibrillar aggregates of the same protein is associated with the neuro-
inflammatory response66,69,70. In addition, it is still widely debated that despite it 
seems to have a negligible role in the pathogenesis of amyloid-related 
neurodegenerative disorders, the presence of mature fibrillary aggregates can 
provocate some symptoms in systemic amyloidoses71. Although the direct causal 
link between Aβ and impaired neuronal function and memory is still under 
elucidation, several studies indicate that cell dysfunction is derived from the ability 
of small aggregates to interact with the cellular membranes, leading to loss of 
membrane integrity and ultimately to cell death72–74. Oligomers interact with 
plasma membrane75,51 affecting important biophysical properties, such as 
microviscosity, molecular order, membrane potential and permeability. 
Membrane lipid composition, especially with respect to the content of cholesterol 
and anionic lipids, plays a fundamental role in determining the nature of 
Aβ/membrane interaction76–79. The neurologically disruptive nature of Aβ 
prefibrillar oligomers has been established in various studies conducted on 
Alzheimer’s80–82, Parkinson’s73,83 , and Huntington’s84, which can induce oxidative 
stress, apoptosis, and abnormal calcium homeostasis in neurons. On the contrary, 
mature fibrils appear to be harmless. 
A deep understanding and visualization of the involved molecular 
mechanisms could lead to new strategies for the treatment of this widespread 
pathology. 
1.3.1 Amyloid β1-42 and Amyloid β1-40  
Aβ peptides are involved in AD as the main component of the amyloid 
plaques found in the brains of Alzheimer patients. Aβ aggregates originate from 
an integral membrane glycoprotein, the Amyloid Precursor Protein (APP). This 
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ubiquitous protein is located in plasma membrane, as well as in endoplasmic 
reticulum, Golgi apparatus, and mitochondria. APP can be metabolized following 
two different pathways85,86 (Figure 1.4): the secretory pathway and the 
amyloidogenic pathway. In the former, occurring more frequently, APP may be 
cleaved between residue 16-17 of the Aβ domain87. The event, called α-secretase 
cleavage, operates in cholesterol poor membrane regions and precludes Aβ 
formation. The soluble α-secretase cleaved APP (α-sAPP) is secreted and the C-
terminal fragment (C83) is processed by γ-secretase, resulting in a not 
amyloidogenic soluble 3-kDa peptide (p3). In the amyloidogenic pathway, The Aβ 
fragment is generated beginning with an initial APP cleavage at amino acid residue 
672 to define the N-terminus of Aβ88. The cleavage is referred to as β-secretase 
cleavage, which is located in cholesterol rich membrane domains, and results in 
the secretion of the soluble β-secretase cleaved APP ectodomain (β-sAPP) from 
neurons and transfected cells. The remaining C-terminal fragment containing the 
transmembrane and cytoplasmic domains (C99).  
After a successive intramembrane cleavage by γ-secretase, amyloid 
peptides consisting in 39-42 residues are released. The Aβ forms in brain deposits, 
Figure 1.4 | The amyloidogenic and non-amyloidogenic processing of APP. Image 
from Ref. 287. 
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which are thought to be more involved in AD pathogenesis, are the ones with 40 
and 42 residues, two isoforms of different length. The 40-residue peptide Aβ1–40 
represents the most abundant Aβ isoform in the brain in vivo89, whereas the more 
aggregation-prone, 42-residue variant Aβ1–42 is the major proteinaceous 
component of the extracellular senile plaques that are the hallmarks of this 
disease90. Despite they only differ by two amino acids in the C-terminal region, yet 
they display markedly different aggregation behavior91. 
Aβ amyloid fibrils have been analyzed with several biophysical and 
biochemical techniques, such as solid-state NMR spectroscopy, Electron 
Microscope (EM), AFM, ThT kinetics studies or mutagenesis27,34,37,92.  
These analyses have provided a wealth of information about specific 
structural details of the peptide in the fibril and the fragment comparison. The 
results obtained by using scanning transmission electron microscopy (STEM), 
suggest that Aβ1-40 and Aβ1-42 share the same fundamental protofilament 
structure. Some different morphologies observed would, therefore, arise mainly 
from the different packing and number of protofilaments93. 
Kinetics study, using fluorescence lifetime imaging (FLIM), shown a clear 
difference between the two peptides to form mature fibrils within live neuronal 
cells. HF488Aβ1-40 appears to exhibit a lag phase in its aggregation, whereas HF488Aβ1-
42 shows no such effect and aggregates rapidly soon after it is internalized into the 
cells94. The latter confirmed by in vitro studies of ThT fluorescence spectroscopy,  
that exhibit a decreasing in the rate constants for Aβ1-40, relative to Aβ1-42, 
indicating higher energy barriers to overcome for all microscopic processes during 
the fibrillation pathway91,95. 
 
1.4 The generic nature of amyloid structure 
One of the remarkable characteristics of the amyloid diseases is that, 
despite the difference between the associated precursor, amyloid fibrils are very 
similar in their overall properties and appereance96. Starting from this evidence, 
several studies, in the last two decays, supported the idea that the ability of the 
protein structure to self-organize into polymeric assemblies is a generic property 
of the polypeptide chains97. In vitro studies report how a range of proteins, with 
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no known connection with any disease in vivo, undergoes conversion in vitro into 
fibrils very similar to those associated with amyloid disease98,99. Since first 
evidence (summarized in Table 1.2)9,100,101 several studies highlight many other 
proteins, unrelated to any amyloid disease, able to form amyloid fibrillar 
aggregates in vitro. This ability occurs under appropriate destabilizing condition, 
e.g. low pH, lack of specific ligands, high temperature, or the presence of specific 
co-solvents, such that the native structure was partially or completely 
disrupted9,102,103. 
 
As already mentioned above, the core structure of the fibrils is stabilized 
primarily by interactions, particularly hydrogen bonds, involving the polypeptide 
main chain. Because the main chain is common to all polypeptides, this 
observation explains why fibrils formed from polypeptides of very different 
sequence seem to be so similar104,105. The propensity to assume fibrillary 
Table 1.2 | Proteins unrelated to diseases that form amyloid fibrils in vitro (Ref. 
from 8, data updated at 2003) 
Domain/Protein Year
SH3 domain p85 phosphatidyl inositol-3-kinase (bovine) 1998
Fibronectin type III module (murine) 1998
Acylphosphatase (equine) 1999
Monellin (Dioscoreophyllum camminsii) 1999
Phosphoglycerate kinase (yeast) 2000
B1 domain of IgG binding protein (Staphylococcus) 2000
Apolipoprotein CII (human) 2000
ADA2H (human) 2000
Met aminopeptidase (Pyrococcus furiosus) 2000
Apocytochrome c (Hydrogenobacter thermophilus) 2001
HypF N-terminal domain (Escherichia coli) 2001
Apomyoglobin (equine) 2001
Amphoterin (human) 2001
Curlin CgsA subunit (Escherichia coli) 2002
Vl domain (murine) 2002
Fibroblast growth factor (Notophthalmus viridescens) 2002




conformation under given circumstances can vary markedly between different 
sequences. The relative aggregation rates for a wide range of peptides and 
proteins correlates with the physicochemical features of the molecules such as 
charge, secondary-structure propensities and hydrophobicity. In a globular 
protein, the polypeptide main chain and the hydrophobic side chains are largely 
buried within the folded structure. The propensity to convert into amyloid fibrils 
increase considerably when the structures are exposed, for example when the 
protein is partly unfolded (e.g. at low pH) or fragmented (e.g. by proteolysis)106. 
The revolutionary discovery that the proteins can undergo fibrillation if 
placed in a specific denaturing condition, represent an important step forward in 
the investigation of amyloid pathologies. Therefore, the capability to reproduce 
the amyloid aggregates behaviour, also in terms of toxicity, employing a highly 
simplified system can offer additional insights into the molecular details of 
amyloid fibril formation107,108. 
This approach is particularly useful, for instance, to obtain very controlled 
processes of aggregation, avoiding the variability displayed in the aggregation of 
some pathological peptides, such as the ones involved in AD, which can be difficult 




1.5 Insulin fibrillogenesis  
In this section, a brief introduction of the model protein employed in this work is 
provided. We have chosen bovine insulin to study amyloid fibrils. The fibrillation 
process of insulin is very well characterized. Moreover, suitable conditions in order 
to obtain fibrils on a timescale that is compatible with the experimental time scale 
can be selected,  making this peptide suited for in vitro experiments60,109. 
1.5.1 The model system: bovine Insulin  
Insulin is a protein hormone with a largely α-helical structure, which plays 
a crucial role in the carbohydrate metabolism and several other body systems, e.g. 
vascular compliance, and it is naturally produced in the Islets of Langerhans in the 
pancreas110. It has been a well-studied fibril-forming protein widely investigated 
and commercially available in large quantities, at reasonable price, resulting as an 
excellent model system to study fibrillation. 
Figure 1.5 | Structure of Insulin. Upper line: From left to right: the monomeric 
hormone (A and B chains) forms dimers via anti-parallel association of B chain α-helices 
and C-terminal β-strands; assembly of three dimers to form hexamer. Images from RCSB 




Primary structure of bovine insulin was reported by Sanger in 1951111,112. 
Mainly the protein is composed of 51 residues located along two polypeptidic 
chains the A-chain, which consists of 21 amino acids, and the B-chain of 30 amino 
acids, linked together by two interchain and one intra-chain disulfide bonds110,113 
(Figure 1.5). Bovine insulin differs from the human type by changing two 
aminoacids in the sequences of the A-chain and one of the B- chain114–116. The 
secondary structure of the A-chain and B-chain consists of two α-helices and a 
combination of one α-helix and a β-strand, respectively. Non-covalent interactions 
between residues of the two chains stabilize the tertiary arrangement and 
determine the structure of the monomer with a hydrophobic core and polar 
residues located on the external surface. Assembling of monomers in higher 
hierarchical species is strongly dependent on physical and chemical parameters of 
the solution as pH, solvent composition, and temperature as well as on insulin 
concentration. 
Several human diseases are related to an aberrant mechanism of insulin 
production. Besides insulinoma, metabolic syndrome, polycystic ovary syndrome, 
a high social impact is represented by the diabetes Type I and Type II related to 
the insulin deficiency and insulin resistance, respectively. Also, amyloid deposits 
have been observed in type II diabetes patients and in normal aging after 
subcutaneous insulin infusion and repeated insulin injections117. Aggregation and 
fibrillation of insulin cause problems during production, storage, and delivery118. 
Actually, during the preparation of recombinant insulin for clinical use, it is 
subjected to low pH, high ionic strength, increased shear, and organic solvents, all 
conditions that promote fibrillation. For all these reasons, in the last decades, the 
insulin-based pharmacological formulation has attracted the interest of many 
researchers.  
Insulin from the bovine pancreas is not an amyloidogenic protein in vivo. 
On the other hand, it has been demonstrated that peptides and proteins that are 
unrelated to disease have a generic ability to form amyloid fibrils upon 




1.5.2 Insulin fibril formation 
Insulin is mainly stored into an inactive form with long-term stability, i.e. 
zinc-coordinated hexamer, while zinc-free insulin is a dimer formed at a low 
concentration over the pH 2-8 range, shifting to a tetramer at protein 
concentrations of >1.5 mg/ml. Nielsen et al. studied the effect of pH on the 
association of human and bovine insulin. At pH 7.4 insulin is hexameric and it 
dissociates upon decreasing the pH. At pH 3 insulin exists as a tetramer, at pH 2.0 
is monomeric in acetic acid and at pH 1.6 insulin is dimeric122. Formation of insulin 
fibrils is a physical process in which non-native molecules interact with each other 
to form linear, biologically inactive aggregates110. The early in vitro studies on 
insulin fibril formation has been shown to result in the formation of insoluble 
aggregates which are rich in β-sheet structures by using infrared dichroism and 
wide angle x-ray diffraction123,124.  
Moreover, in vitro at low pH and high temperature, insulin is very prone to 
form amyloid fibrils125, thus constituting a suitable model system to study some 
different and unknown aspects of the amyloid molecular mechanisms. The model 
has been used both to characterize the mechanical properties of individual 
amyloid fibrils and to determine the growth rate of amyloid fibrils126,127. 
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In the last two decay, regarding insulin protein, many different molecular 
mechanisms responsible for amyloid formation and protein aggregation have  
been  proposed. It has been shown that the formation of insulin fibrils occurs from 
different phases, similar to those described in Section 1.2, in which a number of 
reactions take place.  
Figure 1.6 | Model for nucleus formation and growth from insulin protein in 
acidic environment (a) Prior to nucleus formation, ‘‘elongation’’ dominates; after nucleus 
formation, ‘broadening’’ occurs (from ref. 130). (b) (Right) View of fibril model, looking 
down fibril axis. One layer of fibril model is made by stretching both monomers of native 
insulin (left) in a horizontal direction  converting the deep blue helix of the B chain and 
the deep red helix of the A chain into extended β-strands. The spine of the fibril consists 
of a dry steric zipper formed by the mating of the central two strands from the B-chains 
of the two insulin molecules, plus two outer strands from the A-chains of the two 
molecules (from ref. 288). (c) Surface representation of 3D maps of the four insulin fibril 
structures. (From left to right) Structure of the fibril with a pair of protofilaments twisting 
around each other. The four-protofilament compact fibril. The six-protofilament fibril. 
The twisted ribbon. The protofilaments are well resolved in the first three structures, but 
are less clear in the twisted ribbon (from ref. 36). 
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Nielsen et al. conducted insulin aggregation studies with human insulin, 
bovine insulin and insulin mutants at various conditions, including incubation at 
60 ˚C, pH 1.6 at insulin concentrations of 2 mg/ml. All of their kinetic results was 
monitored by the fluorescent probe, thioflavin T, and shown to be consistent with 
a nucleation-dependent elongation mechanism via the initial formation of a 
partially folded intermediate conformation124. They concluded that both 
nucleation and fibril growth were influenced by external factors, such as 
hydrophobic and electrostatic interactions122. Several other studies highlight how 
this process can be influenced, in term of time, by other growth mechanisms such 
as secondary nucleation (the presence of already formed fibrils in solution)128 and 
the behaviour of insulin fibrillation in confined environments129. 
Furthermore, the measure of the temporal formation of insulin oligomers, 
in different solvents, by small-angle neutron scattering (SANS), suggest a universal 
pathway for amyloid nucleus and precursor formation using insulin model130. This 
study suggests that, as described for β-amyloid peptide oligomers by scanning 
tunnelling microscopy and small-angle x-ray scattering123,131, as well for insulin, 
the elongation occur by the assembly of individual monomers to the growing fibril. 
In addition, studies during the early stages of in vitro fibrillation of insulin, 
demonstrate that the generated nucleus, during the initial critical phase, 
comprises three dimer units or six monomeric units. The nucleus of three 
cylindrical-shaped insulin dimers join end-on to form a hexameric nucleus 
(elongation in Figure 1.6a) which then aggregates side-on with other nuclei and 
preformed aggregates leading to the formation of protofilaments (broadening in 
Figure 1.6a). SANS data on insulin molecules showed that prior to nucleus 
formation, the length of the precursors increases linearly while their radius 
remains constant. After nucleus formation, the radius increases as per the close 
geometric packing of the cylinders, and length increases by about 1/12th of the 
nucleus length due to sliding of the adjoining nuclei130. 
A more thorough knowledge of the structure and mechanism behind the 
formation of amyloid fibrils in general is essential for the understanding of the 
processes of amyloidosis. In the next sections, we are going to propose a new and 
original approach in the investigation of protein aggregation by using an advanced 
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integrated system obtained from the coupling of a standard atomic force 
microscope and a super-resolution optical microscopes. I disclose some limits that 
are inherently related to fluorescence methods. 
 
1.6 – Amyloid cytotoxicity 
One of the most essential aspects in the plasma membrane study is that a 
physiological alteration can bring about numerous pathological consequences. For 
several years a misleading theory about the nature of the toxic agent in 
Alzheimer's, Parkinson's (the most known diseases that involve protein 
deposition), and other degenerative age-related diseases took place. For years, 
most researchers have backed the notion that clumps of long amyloid fibrils 
located in the brain and other organs are responsible for killing neurons and other 
cells. In Alzheimer's, these clumps are termed amyloid plaques and consist 
primarily of the polypeptide amyloid β protein; in Parkinson's, they are called Lewy 
bodies and contain the protein α-synuclein. 
An increasing quantity of recent experimental data suggests, however, that 
in many cases at least the species that are most highly toxic to cells are the pre-
fibrillar aggregates (sometimes referred to as amorphous aggregates, protein 
micelles or protofibrils) rather than the mature fibrils into which they often 
develop73,84,136,250. In particular, a number of reports concerning Aβ-peptides, -
syn and transthyretin indicate that these early aggregates are the most toxic 
species135,251–254; in addition, the presence of such species has also been reported 
for huntingtin and possibly the androgen receptor255 in diseased transgenic mice.  
Such toxicity is likely to arise from the ‘misfolded’ nature of the aggregated 
species and their precursors and from the exposure of regions of the protein (e.g. 
hydrophobic residues and the polypeptide main chain) that are buried in the 
native state. As many of these regions are likely to be aggregation-prone (or 
‘sticky’) they may be able to interact with membranes and other cellular 
components72. Indeed, in an ensemble of small aggregates containing misfolded 
polypeptide chains there will be a vast array of exposed groups of amino acids, 
some of which may mimic regions of the surfaces of native proteins. Such 
aggregates are therefore likely to be able to interact inappropriately with the 
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binding partners or receptors of a wider range of different proteins. Indeed, the 
intrinsic instability of pre-fibrillar species that enables them to assemble further 
and become organised into more highly ordered structures itself reflects the 
existence of accessible regions of the structures. 
In agreement with these conclusions, pre-fibrillar assemblies have been 
shown to interact with synthetic phospholipid bilayers and with cell membranes, 
possibly destabilising them and impairing the function of specific membrane-
bound proteins256–258.        
In particular, it was observed how the membrane lipid composition, 
especially with respect to the content of cholesterol and anionic lipids, plays a 
fundamental role in determining the nature of amyloid protein/membrane 
interaction74,76,77,259. The exact mechanism by which amyloid peptide cause 
damage to the cell is still an open question. The answer may be found in the 
interaction with the cell interfaces area51,84,260. Several studies performed on cells 
and model systems indicate that toxic oligomers can permeabilize the cell 
membrane through the creation of pore-like structures261–263, altering the 
physiological ionic balance (Figure 1.7).  
 
The membrane itself can act as a catalyst for fibrillization264,265. Another 
option is that aggregates  interfere with the normal cell processes  occurring at the 
plasma membrane level, binding some portions of the external leaflet266,267, or 
penetrating inside the double layer of phospholipids, causing variations in 
important membrane properties such as fluidity268. Other experiments suggested 
Figure 1.7 | Electron microscopy image of prefibrillar aggregates. The images 
refer to the α-syn mutant (A53T) aggregation, involved in Parkinson’s disease. In the 
first stage of aggregation the protein shows a characteristic pore-like structure290. The 
images show an area of 30.5x30.5 nm. 
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that the main toxic effect is membrane disruption269,270,which could happen via a 































Chapter 2  
Microscopy techniques  
 
In this Chapter, I describe the techniques used in this work. The first part is 
focused on optical fluorescence techniques, with a brief introduction to confocal 
microscopy. Specific attention is focused on the reference of super-resolution 
microscopy. The second part is centered on the scanning probe principles, with a 
specific overview on AFM.  
The field of optical microscopy dates back to at least the 17th-century. It 
was not until the German mechanic Carl Zeiss started producing microscopes in 
the late 19th century that a more reliable method was established142. Employing 
the Abbe’s formula for the calculation of the maximal resolution achievable from 
an optical microscope, published in 1873, an essential milestone in the history of 
microscopy was achieved143. According to this, the lateral resolution, d, i.e. the 





,where λ is the wavelength of the light, NAobj is the numerical aperture of 
the objective, and NAcond is the numerical aperture of the condenser. Numerical 
aperture is defined as the refractive index of the imaging medium (n) multiplied 
by the sine of the aperture angle (α): NA= n sin(α). Additional enhancement has 
been made to the basic design of the optical microscope. One such modification 
has been the development of fluorescence microscopy to look at samples that 
hold fluorescent properties. Fluorescence microscopy has become an 
indispensable tool in biology and in life sciences because of its unique advantages: 
it is a largely non-invasive technique and it can probe the deeper layers of a 
specimen at ambient conditions and enables spectroscopic diagnosis with 
chemical sensitivity. The photophysical process in a conventional fluorescence 
microscope is best described by Jablonski diagrams144 (Figure 2.1). Even though 
fluorescence microscopy has enabled an improvement in visual perception, the 
resolution is ultimately restricted by the, above mentioned, diffraction limit and, 
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further, by the conditions imposed by the Rayleigh criterion. It is possible to 
increase resolution by using short wavelength excitation sources and by increasing 
the numerical aperture of the objective lens, which thus increases the area over 
which the objective collects light from the sample. This, however, does reach a 
limit in experiments when the length scale of a sample reaches around 200-300 
nm, in line with the λ/2. 
In this scenario, several advanced concepts aimed at pushing the 
diffraction limits by reducing the focal spot size. Confocal fluorescence 
microscopy145, described in the next section, is one of them. 
Importantly, in 1994, by Hell and Wichman146 STED super-resolution 
technique was introduced, breaking the diffraction limit. 
Due to the intrinsic resolution limitations imposed on optical microscopy, 
other forms of microscopy are required to probe objects past the diffraction limit. 
One such technique is that of scanning probe microscopy147, which can measure 
Figure 2.1 | Simplified Jablonski energy diagram representing fluorescence. The 
purple arrow represents the absorption of light. The red arrow represents vibrational 
relaxation from singlet-excited state, S2 to S1. This process is a non-radiative relaxation in 
which the excitation energy is dispersed as vibrations or heat to the solvent and no photon 
is emitted. The green arrow represents fluorescence to the singlet ground state, So. 
(Image from Wikimedia Commons) 
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both surface topography at the atomic scales. One of the most useful and largely 
utilized forms of scanning probe microscope is the AFM.  
Considering that every technology entails have intrinsic limitations, I 
thought that correlative techniques are a necessary step towards the achievement 
of a richer set of informations. 
Figure 2.2 | Schematic configuration of laser scanning confocal microscope 
optical setup. The light coming from the laser passes an (excitation) pinhole, and a 
dichroic mirror rejects it and focused by a microscope objective to a small spot on the 
sample. A dichroic mirror reflects one wavelength while transmits the others All the light 
originating from the in-focus plane will pass freely through the pinhole, whereas the 




2.1 Confocal microscope  
In many areas of current research interest, such as cellular biology, 
Confocal fluorescence microscopy result to be a useful approach. Due to the 
relative ease with which extremely high-quality images can be collected from 
specimens prepared for conventional optical microscopy, it has been extensively 
employed. The confocal principle relies on upon enhancement of both lateral and 
axial resolution, overcoming the limitations of the traditional wide-field 
fluorescence microscopes. Since the development of the ‘automated scanning’ 
concept using a fluorescence microscope148 and the first optical sectioning 
design149, it has been gave the opportunity to produce the first clear images of 
focal planes deep within a thick sample, leading to the development of the laser 
scanning confocal microscope150. 
In a conventional fluorescence microscope, in which the entire sample is 
flooded with light from a light source, all the sample within the optical path is 
excited at the same time. Consequently, the fluorescence detected by the 
microscope's photodetector is comprising a large unfocused background part. In 
contrast, the confocal microscope bases its working principle on the introduction 
of a small aperture (pinhole) in order to eliminate out-of-focus signal. In detail, 
both of the laser beams, focused on the specimen, and fluorescence light emitted 
by the dye molecule, are passing through a small pinhole before reaching the 
photomultiplier (detector). The focal point in the sample and the pinhole lie in 
conjugate planes; this optical arrangement is called ‘confocal’. Since only the light 
from the focal point can pass the pinhole and can be measured by the detectors151, 
the resolution increases but at the expense of decreasing signal intensity. It should 
also be specified that the resolution in confocal microscopy is limited by the size 
of the focal spot. The full-width half-maximum (FWHM) radius (Δr) of the focal 
spot produced by an objective with numerical aperture NA=nsinα focusing light of 
wavelength λ is 







,where n is the refractive index of the medium in which the objective is 
working and α is the maximal half-angle of the light cone that can exit the lens.  
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For a typical oil immersion objective (n = 1.516), an objective with NA = 1.4 
and light of wavelength λ = 640 nm the FWHM of the focal spot would be about 
230 nm. This would not allow a detailed observation of nanometric features, such 
as the amyloid fibrils investigated in this work152. Figure 2.2 shows the scheme of 
the optical path in an inverted configuration of a modern confocal microscope. 
 
2.2 Super-resolution fluorescence techniques 
In the last two decays, a series of original approaches open the way to a 
new class of far-field microscopy, defined as SR optical microscopy or merely 
nanoscopy techniques, that shattered the diffraction barrier, improving spatial 
resolution by an order of magnitude or more over the diffraction limit. These 
techniques have the potential to provide new insights into biological processes at 
the, hitherto inaccessible, molecular scale suggesting new amazing applications 
for the next future153. 
The use of light in far-field optical nanoscopy has been brought to the 
forefront with the 2014 Nobel Prize for chemistry154, with fluorescent stimulated 
emission depletion microscopy (STED). It was achieved a real optical lateral 
resolution of  ̴30 nm and single-molecule microscopy capable of revealing intra-
cellular details of tens of nm using the super localization of fluorescent marker 
molecules155–157. Several other techniques, as well as STED, in the field of SR optical 
techniques are based on the use of fluorescent molecules. , such as stochastic 
optical reconstruction microscopy (STORM)158–160, photoactivation localization 
microscopy (PALM)161, reversible saturated optical fluorescence transitions 




2.2.1 Stimulated Emission Depletion Microscopy (STED) 
Stimulated emission depletion (STED) fundamentally overcome the far-
field diffraction limit in fluorescence microscopy. The underlying idea is to switch 
the marker molecules in a controlled way between a bright (fluorescent) state and 
a dark state165. The switching is performed by utilizing the process of stimulated 
emission. As shown in figure 2.3, compared with a conventional confocal microscope, 
it uses, in addition to a fluorescence excitation laser, a second, ring-shaped laser 
to quench fluorescence. In particular, in order to switch off the ability of the 
markers to fluoresce, a second beam of light inducing the stimulated emission, 
called STED beam, is overlaid to the focal spot of the excitation laser. The depletion 
laser is spatially shaped into an optical vortex beam, commonly referred to as a 
doughnut beam such that it has an intensity minimum at its centre (coaligned with 
the maximum of the excitation laser). This confines fluorescence emission to the 
centre of the focal spot and reduces the size of the effective focal spot from which 
fluorescence can be emitted. The technique is derived from the Confocal basic 
Figure 2.3 | (a) Conventional confocal microscopy compared with Stimulated 
Emission Depletion (STED) nanoscopy. It uses (in addition to a fluorescence excitation 
laser) a second, ring-shaped laser to quench fluorescence. (b) Schematic configuration 
of STED system. (Image from http://zeiss-campus.magnet.fsu.edu). 
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principle thereby the coaligned depletion and excitation beams are scanned across 
the sample165. 
A complete depletion from the periphery of focal volume can be ensured 
by increasing the number of events, which is simply done by increasing the 
depletion laser intensity in this doughnut-shaped depletion focus and thence 
gaining a higher resolution. The use of the STED on biological material sets limits 
on the depletion laser intensity since the sample can easily undergo to photo-
damages166. Besides, the power of the STED depletion laser source is limited 
through a photobleaching effect, i.e. an irreversible chemical degradation of a 
fluorophore into a non-fluorescent species, when the intensity is too high. The 
phenomenon occurs from excited states where molecules have more energy and 
a greater probability of reacting with their surroundings, becoming non-
fluorescent (photobleached). In this regard, it is necessary to find the right balance 
between lost of information and lost of resolution167,168. 
Since the first work describing STED microscopy as super-resolution 
method in 1994 by Hell et al. and its demonstration in 2002 a range of STED 
methods have been developed based around this principle169. In general, these 
techniques differ in the type of laser used for depletion, pulsed or continuous 
wave (CW), and the depletion intensity required for a given resolution. The STED 
pulses beam, despite the highest efficiency with the lower average power, require 
synchronization with their excitation counterparts. The apparent need for 
sophisticated pulse preparation hampered the wider use of this technique170. In 
order to greatly simplifies the system, STED microscopy has been implemented 
with CW lasers, making the use of pulses obsolete in many cases. Among the 
greatest challenges for implementing microscopy is choosing suitable fluorescent 
probes due to the potential involvement of fluorescent dark states in 
photobleaching. In short, the fluorophores trapped in the triplet state must be 
able to relax to the ground state before the depletion beam moves to the next 
spatial location. It has been suggested that STED with CW lasers can be further 
improved by using time-gated detection which rejects lower resolution early 
emitted photons171. Viable for fluorophores with low triplet yield, the use of time-
gated modes coupled with CW light sources (gCW-STED) greatly simplifies the 
45 
 
implementation of this concept of far-field fluorescence nanoscopy, opening the 
way for a versatile tool for biological nanometer scale investigation166. 
 
2.3 Scanning Probe Microscope – the blind 
microscope 
The history of SPM starts in 1981 with the invention of the first member of 
the family, the scanning tunnelling microscope (STM) by Gerd Binnig and Heinrich 
Rohrer, that led to winning the Nobel Prize in 1986172. The revolutionary 
microscope was capable of displaying the topography of surfaces down to atomic 
resolution. The invention constituted a major breakthrough in the field of physics. 
SPM techniques are based on the interaction between the sample and a sharp 
probe, which is scanned over its surface following a raster path. SPM scanners are 
made of piezoelectric ceramic materials, which can experience a mechanical 
deformation if an electric potential is applied, allowing the very accurate 
displacement of the tip. The most commonly used SPM scanners are piezoelectric 
tubes capable of controlling probe movements in X, Y, and Z at the same time. 
However, in recent years the use of flexure scanners, based on piezoelectric stack 
Figure 2.4 | (a) Schematic representation of a Scanning Probe Microscope. b) 




actuators, is generally preferred, since they allow a complete decoupling of 
motions in different directions, avoiding the intrinsic non-linearity of piezoelectric 
tubes. 
During imaging acquisition, the interaction between the sample and the 
probe generates a signal at each scanned point (cantilever deflection, cantilever 
amplitude/frequency of oscillation). Such signal depends on the distance between 
the probe and the sample allowing the reconstruction of surface topography. SPM 
system can work in either in constant-height mode or constant-signal mode 
(Figure 2.4). In the first, the vertical position of the probe is kept constant, and the 
relative probe-sample distance is directly derived from signal measurement. 
Whereas, in constant-signal mode a Z-feedback loop controls probe vertical 
position in order to obtain a specific signal value; the topography is then 
reconstructed considering the vertical displacement of the piezo. The constant-
height mode is faster and extremely sensitive. On the other hand, due to the 
uncontrolled probe-sample distance, the probe can heavily damage the sample. 
Constant height mode can be used only on flat samples and for small scan areas.  
In scanning tunneling microscopy (STM) measurements, a bias voltage is 
applied between a conductive or semi-conductive sample and STM probe, which 
consists in a sharp, conductive tip. When the tip gets close enough to the sample 
(typically 10 Å far), electrons start tunneling through the gap. The tunneling 
current detecting result extremely precise and depend exponentially on tip-
sample distance, allowing imaging of conductive or semi-conductive flat surfaces 
with an atomic resolution. 
 
2.3.1 Atomic Force Microscopy (AFM) 
The AFM is considered the most successful member of the SPM family. 
Since the origin in 1986173, It has been demonstrated to be a powerful tool for 
imaging biological samples in physiological-like conditions, resolving single 
molecules and without any label or sample treatments. The significant advantage 
of AFM, concerning STM technique, is that it also works on insulating samples. 
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Furthermore, it operates in a large number of working conditions, including air, 
vacuum, and liquid.  
Working principles 
Its working principle is based on the interatomic forces between the probe, 
generally a sharp tip attached to a suspended cantilever, and the sample. The 
probe consists of a sharp tip, with a typical radius of curvature (ROC) of 10–30 nm 
that is attached to the free end of a micro-machined cantilever. The probe 
cantilever is brought very close to the sample, enabling the tip atoms to interact 
with the atoms of the sample. These interaction forces deflect the cantilever and 
the changes in either the static deflection or its dynamic properties are measured 
to extract the image174. The AFM tip perceives two different force regimes. These 
forces, described by Lennard-Jones potential (Figure 2.5a) are characterized by a 
long-range attractive regime, that include the van der Waals, magnetic and 
electrostatic forces with an interaction range up to 100 nm, and  by a short-range 
repulsive regime, due to the overlapping of electron clouds and to the repulsion 
between atomic nuclei. 
However, the force exerted by the sample on tip induces a bending on a 
cantilever. The most employed approach for quantifying cantilever deflection is 
the one based on optical lever principle175. In this detection system (Figure 2.5b), 
Figure 2.5 | (a) Lennard-Jones potential (red curve), describes interactions 
between atoms depending on their distance d. It results from the sum of two 
contributions, related to attractive and repulsive interactions (Image from 
http://www.uni-leipzig.de). (b) Simplified scheme of AFM photodetection system 
(optical path elements are not shown). Cantilever deflection results in a shift in laser 
spot position on PSPD. AFM main signal (vertical deflection) is calculated from (A+B)-
(C+D), while frictional torsion (lateral deflection) is (A+C)-(B+D). 
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a laser beam is focused on cantilever surface, which is coated with a reflective 
material. The laser spot is reflected on a position-sensitive photodetector (PSPD), 
which generates a proportional voltage signal. In the absence of interaction, laser 
reflection is centered on the PSPD. Cantilever bending causes a shift in laser spot 
position on PSPD, which is proportional to cantilever deflection. Four segments 
compose PSPD used in AFM, allowing the detection of both vertical and lateral 
deflection176. 
The cantilever probe is basically a force transducer. It senses the 
interaction between the tip and the sample and transforms it into a measurable 
bending of the cantilever. The force is obtained by applying Hooke’s law: F = -kd, 
where F is the force exerted by the sample on the tip (and vice-versa), and d 
represents the vertical deflection. The elastic constant k depends on cantilever 
geometry: short, thick cantilevers present high k values, while long, thin 
cantilevers are softer. Reference k values are generally reported for commercial 
probes, but, if we are interested in knowing exactly the applied force, it is 
advisable to calibrate each cantilever before measuring. This can be done, for 
instance, using the thermal noise method177. After calibration, force can be easily 
derived from the measured deflection. 
AFM Imaging mode  
AFM probe can sense objects operating in different modes, depending on 
the type of sample and on the nature of tip-surface interactions. The main 
operating modes are indicated as contact mode (static method), intermittent 
Figure 2.6 | AFM imaging modes (modified from 289). 
49 
 
contact mode, non-contact mode, and force modulation mode (dynamic 
methods), which exploit different interaction force regimes (Figure 2.6). As 
previously discussed, the most frequently used configuration is constant-signal 
mode in which Z-feedback loop is active and works to keep a measured variable 
constant, matching it with a chosen setpoint value. 
Contact imaging mode operates in repulsive regime where the tip is 
pushing on the sample and positive force values are measured. Before starting, a 
force setpoint is chosen, generally low, in order to reduce the interaction with the 
sample. A feedback control system, during the scan, compares the measured force 
with the setpoint, driving the piezo in order to maintain the force constant. 
Contact mode provides the highest resolution and highest stability in AFM 
imaging. 
In intermittent contact mode the tip oscillates near the surface with a 
frequency close to the resonance of the system. The amplitude of oscillation of 
the cantilever is the feedback parameter that is maintained constant during the 
scan, i.e. the more the tip gets close to the sample, the more the free oscillation 
amplitude is reduced.  Intermittent contact involves both repulsive and attractive 
regime. Since the tip detect the sample in the lower part of the oscillation 
(repulsive contact force), the interaction with the sample is extremely reduced 
with respect to contact mode, as well as the lateral force exerted during scanning. 
Therefore, intermittent contact should be preferred in case of soft, delicate 
samples, such as the biological ones. 
Other kind of information can be indirectly derived from these main 
acquisition methods: in contact mode, for instance, lateral deflection describes 
the friction between tip and sample178, while in intermittent contact different 
materials can be distinguished from the phase shift, which they induce between 
the driving signal and the detected one. These secondary imaging modes 
represent a valid tool for investigating the properties of different sample 
components179,180. 
Force spectroscopy technique and related methods 
The AFM tool is able to obtain other valuable information on sample 
properties in addition at the capability to perform high-resolution images, even 
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simultaneously. The cantilever, in fact, can be moved along vertical direction on a 
fixed X-Y position. Starting from a distance far from the sample where the tip-
sample interaction is null, the cantilever is approached toward the sample until 
contact occur and a certain deflection (setpoint) is reached. At this stage, the 
cantilever is retracted and brought back to the starting situation. The force acting 
on the tip is measured and plotted against piezo displacement, generating a force-
distance curve181 (Figure 2.7). There are a huge number of applications of force 
spectroscopy, from nano-mechanical investigations of elastic properties to protein 
unfolding and studies of single chemical bonds. In the last years, a large number 
of application are related to biological field182,183. 
The designed method ‘Force Volume’ concern the acquisition of Force-
distance curves on different X-Y position of the sample, possibly regularly spaced 
in a grid, and also in Z position, collecting the data points in a tridimensional space. 
The topography of the corresponding area can be obtained as well as in a 
conventional contact-imaging mode. Height information can be derived for each 
X-Y point, during the movement performed by the piezo to reach the maximum 
force setpoint. Furthermore, the information extracted from force-distance 
curves, representing local physical properties of the sample, can be remapped 
with a direct reference to the topography. This process can be done automatically 
during real-time measurement, but in most of the cases it requires a post-
Figure 2.7 | Schematic representation of a force vs distance curve. 
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processing. The main drawback of conventional Force Volume is that curve 
acquisition is extremely time-consuming. Different techniques have been 
developed to obtain high-speed force volume, including Bruker Peak Force and JPK 
Quantitative Imaging (QI) mode. In QI mode, the X-Y position is maintained 
constant during each FD curve acquisition allowing the lateral movements of the 
tip to be carried out without any interaction between the tip and the sample. This 
feature can be exploited to image the sample avoiding dragging artefacts, in which 
the force setpoint is maintain as low as possible, to avoid sample deformation184. 
 
2.4 Correlative Nanoscopy  
Correlative nanoscopy is a new term coined from microscopy methods 
which correlate two or more different techniques that can visualize and study 
nanometer-scale details of the sample185. Despite the improvement obtained in 
the field of microscopy, every single technology entails some intrinsic limitations. 
Table 2.1 describe advantages and limitations of high-resolution imaging 
techniques186. The aforementioned AFM technique, for instance, because its 
ability to work in liquid, controlled conditions (temperature, pH, ionic strength, 
etc.), and label-free has been considered a preferred method to characterized 
Table 2.1 | Comparison of high-resolution imaging techniques in molecular and 


























Freeze/critical point drying 
and metal shadwing
Artefacts Tip, force, scanning Bleaching, toxicity





Imaging under native 
conditions; no staining, 
labelling or fixation 
necessary; high signal-to-
noise ratio; assessment of 
multiple physical, chemical 
and biological parameters
Access to three-dimensional 
cellular structure; high 
spatiotemporal resolution; 
monitoring biomolecular 
processes in life cells
Solve atomic structures of 
proteins; conformational 




Imaging surfaces of 
tissues, cells and 
interfaces at nanometre-
scale resolution
Limitations Restricted to surfaces
Imaging restricted to 
fluorescence labels
No life processes No life processes
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biological structure. On the other hand, in spite of this wide range of 
demonstrated abilities, this technique alone does not allow the specific 
identification of individual elements of a heterogeneous sample. This limitation 
could be restrictive in some molecular environments, such as multi-proteins 
aggregation or biomembrane .  
Fluorescent microscopy is a very popular tool expecially in biological 
science due to its ability to noninvasively image in all-spatial dimension. Attaching 
fluorophores to the molecule of interest with antibody, direct covalent labelling 
or genetic modification is highly specific, enabling sensitive measurement with low 
background. The use of fluorescent molecules is a key procedure, because, 
properly labeled, produce the main signal at the basis of the image formation 
process. Actually, an affordable technique to control (visualize) the fluorophore 
distribution within the sample, as well as the rise of unpredictable anomalous 
processes induced by the fluorophore, and that occur locally on a submicron scale, 
is missing. Several attempts to overcome this limitation were made in the past 
decades. Moreover, because of the high complexity of biological system a single 
type of technique is often not enough to obtain an exhaustive characterization of 
the sample itself. For this reason, the coupling of high-resolution systems could 
unravel mechanisms that are still open. The study proposed in this thesis was 
carried on through the use of a technique that combined STED microscopy and 
AFM.  
2.4.1 AFM/STED techniques  
AFM can be complemented by optical microscopy in many ways. This can 
include using the faster imaging speed of an optical microscope to quickly screen 
a sample and select regions of interest for high resolution AFM imaging187,188 or 
combining chemical identification – from fluorescent labelling of the sample – with 
high resolution AFM imaging to correlate structure with chemical species189. In 
particular, AFM has been correlated with confocal microscopy imaging of the actin 
cytoskeleton however, due to the limited  optical resolution, actin filaments in 
dense structures could not be observed187. Therefore, it has been necessary 
integrate an optical microscope with a lateral resolution as close as possible to 
that achieved by scanning probe techniques. In the last years, applications of  SR 
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techniques integrated with AFM have been reported on vitro cells190,159, opening 
the way to new modalities, e.g. nanomanipulation191,192. 
In Figure 2.8 a schematic representation of a combined AFM/STED 
microscope is shown. The setup and the calibration system will be described in 














Figure 2.8 | AFM/STED Schematic representation. The confocal and STED 
images are acquired in reflection, while the AFM probe is reaching the sample from 




AFM/STED correlative on proteins 
aggregation 
 
This chapter provides a description of the methodology used during my 
PhD. The main objective was to obtain new insights on the aggregation process 
followed by a mixture of fluorescently labeled and unlabeled. For this purpose, it 
has been proposed a new approach in the study of misfolded protein aggregation, 
based on the use of a combined system that couple the capability of an AFM, a 
primary technique in the study of amyloid aggregation in vitro, with that of a 
stimulated emission depletion (STED) microscope. In particular, amyloid 
aggregates derived from insulin and two different alloforms of β-amyloid peptides, 
Aβ1-42, and Aβ1-40 were investigated.  
The aggregation process of the peptides was also followed by standard 
methods (ThT fluorescence, dynamic light scattering and AFM). These techniques 
were presented in the first part of the Materials and Methods, together with the 
labeling methods employed. Experimental details of AFM/STED correlative 
nanoscopy are described in sections 3.9.  
 
Materials and Methods 
 
3.1 - Insulin labeling  
Bovine insulin was purchased from Sigma-Aldrich (St Louis, MO, USA) and 
used without further purification. The protein was labeled with fluorescent dyes, 
ATTO 488 NHS ester (Sigma-Aldrich, St Louis, MO, USA). NHS-esters readily react 
with amino groups of proteins, i.e., the ε-amino groups of lysine or the amino-
terminus, forming a chemically stable amide bond. In step 1 of figure 3.1, the 
potential binding sites on the monomeric insulin structure are shown.  
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Labeling was done in a solution of sodium bicarbonate 100 mM at pH 8.3, 
and mixing monomeric insulin at a final concentration of 2 mg/ml (0.35 mM), with 
1 mM ATTO 488, previously diluted in dimethylsulfoxide (DMSO) (Thermofisher, 
Waltham, MA, USA). 
After 1 hour under stirring, the proteins were separated from the excess of 
free dye via filtration with Amicon Ultra, centrifugal filters (MWCO 3K, Merck 
Millipore, Milan, Italy) (Figure 3.1 – step 2). Immediately after filtration the 
concentration of the labeled proteins was determined spectrophotometrically 
(Ɛ280nm 5840 M-1cm-1) (Cary spectrophotometer, Agilent, Technologies, Santa 
Clara, CA, USA) (Figure 3.1 – step 3) and adjusted at 1 mg/ml. The unlabeled insulin 
monomers were added in HCl solution, pH 2,  to a final dye-to-proteins ratio (i.e., 
labeled: unlabeled insulin) of 1:19, 1:99 and 1:499 (Figure 3.1 – step 4). 
 
3.2 – Labeled and unlabeled Insulin fibrillogenesis 
The fibrillation solution consists of pH 2 Hydrochloric acid (HCl) 37% 
(Sigma-Aldrich, St Louis, MO, USA) diluted in deionized water. Insulin is dimeric 
under this condition110,193 (Figure 3.2). Lyophilized insulin peptide was dissolved, 
at the final concentration of 1 mg/ml (0.2 mM), in HCl solution. 
Figure 3.1 | Schematic representation of Insulin Labeling procedure. In Step 1 
labeling of insulin. The following step are: Step 2, purification; step 3, quantification; step 
4, final solution of labeled and unlabeled insulin in three dye-to-protein ratio; step 5, 
fibrillation process.  
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The aggregation was performed on unlabeled insulin or mixed solution 
at different dye-to-protein ratio (i.e., number of labeled:unlabeled insulin 
monomers) 1:19, 1:99 and 1:499. 
Fibrillation of labeled (described in section 3.1) and unlabeled insulin 
peptides took place at 60°C in glass vials, without agitation60. AFM was used to 
verify the fibrillation process in the presence and without fluorescent molecules. 
The aggregation process was followed for at least 2 weeks. Immediately 
after the incubation time, the protein samples were diluted 100 times with water 
and applied onto freshly cleaved muscovite mica for AFM control measurements 
and on microscope coverslip for AFM/STED images. The dilution of the samples 
with water immediately quenches the aggregation process. Moreover, for dry 
condition measurement, deposition on the mica surface is followed by a gently 
drying procedure by means of a low nitrogen flow to obtain water evaporation, 
which eventually prevents further aggregation. Successively, AFM images have 
been taken for each sample. 
 
3.3 – Fibrillogenesis of unlabeled and labeled Aβ1-
42 and Aβ1-40  
Lyophilized synthetic human Aβ1-42/Aβ1-40 (Bachem, Bubendorf, 
Switzerland) were dissolved in 100% hexafluoroisopropanol (HFIP) solution 
(1mg/ml), aliquoted and then stored at -20°C. The storing buffer HFIP is used to 
Figure 3.2 | Molecular structure of dimeric insulin at pH 2.0. (a) Ribbon structure 
showing the secondary structural motifs, and (b) space filled representation of the same 
dimer. The length and diameter of the cylinder was estimated to be 42 and 22 Å, 
respectively193. (Image from ref. 130) 
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avoid aggregates formation before starting the incubation. Beside solvent 
evaporation, fibrils were prepared by incubating the Aβ protein in 50 mM sodium 
hydroxide.  
Synthetic Aβ1-42/Aβ1-40-HiLyte Fluor 488 (HF488) (Anaspec, San Jose, CA, 
USA) were dissolved in 1% Ammonium hydroxide solution (1mg/ml), aliquoted 
and then stored at -20°C. Labelled peptides were used without further 
purification. Fluorescently labeled amyloid fibrils were prepared by dissolving 
unlabeled Aβ in saline phosphate buffer and adding HF488 labeled Aβ to give a 
final dye-to-protein ratio 1:19, 1:99 and 1:499 at the 25 µM final protein 
concentration.  
Unlabeled and labeled protein solutions were sonicated for 5 min and 
centrifuged for 10 min at 15000 rcf to separate possible aggregates. The pelleted 
fractions were discarded, and the supernatant was incubated at 25°C for 1 day 
without agitation194. AFM and DLS were used to exclude the presence of pre-
aggregated peptides at the beginning of the fibrillation process. The samples were 
deposited on the substrate (as previously described for insulin), rinsed with 
deionized water to remove salts and dried under a mild nitrogen flow before 
AFM/STED imaging. 
 
3.4 – Immunolabeling analysis of Aβ1-42 peptide 
Labeling of the fibrils was done by standard immunofluorescence staining. 
Aβ1-42 was prepared as above described in 3.3 section and, a drop of solution after 
1 day of aggregation in vitro was deposited on the microscope coverslip previously 
cleaned and treated with 1M MgCl2. The fibrils were then slightly rinsed, and 
incubated overnight with mouse monoclonal Aβ1-42 antibody (Abcam, Cambridge, 
UK), diluted in 1% BSA (Bovine serum albumin). The primary monoclonal antibody 
recognize specifically the amino-terminal residues 1-17 of human Aβ. The samples 
were rinsed three times with 1% BSA and then incubated with Alexa Fluor 488 
secondary antibody (Sigma-Aldrich, St Louis, MO, USA), diluted in 1% BSA for 2 




3.5 - Thioflavin T assay 
ThT were purchased from Abcam (Cambridge, UK). The stock solutions 
were prepared by dissolving   ̴30 mg dry powder in 1 ml water. The solution was 
filtered through 0.22 μm syringe filters and stored protected from light at 4°C for 
less than 2 weeks. ThT solution was diluted at different concentration for each 
proteins. The final concentration of 100 µM with 50µM of insulin protein, while 
ThT at 50 µM with 25µM of Aβ has been used. A twofold molar excess of ThT is 
used to ensure saturation of the binding sites. The fluorescence was measured 
using FluoroMax-4 spectrofluorometer (Horiba Jobin Yvon Inc.) using an excitation 
of 450 nm42. The time evolution of emission maximum which is taken in account 
as fluorescence intensity measure observed was in the insulin-bound ThT at 490 
nm, while in Aβ-ThT at 488 nm. 
 
3.6 - Light scattering. 
Dynamic light scattering (DLS) measurements were performed with a 
Malvern instrument Zeta Sizer NanoZS system (Malvern Instruments Ltd., 
Figure 3.3 | (a) JPK Nanowizard III with Zeiss inverted optical microscope. (b) 
Motorized stage with sample holder. (c) Cantilever holder. (d) Description of JPK 
Nanowizard III. Images modified from: http://www.jpk.com. 
59 
 
Worcestershire, UK) at a protein concentration of 0.05 mg/ml Aβ1-42 and Aβ1-40 
was dissolved in water, after pretreatment 100% hexafluoroisopropanol and 
centrifugation for seed removal. The measurements were done immediately after 
10 min centrifugation at 15000 rcf. 
 
3.7 - Atomic Force Microscopy measurements 
AFM control measurements were performed by using a Nanowizard III (JPK 
Instruments, Berlin, Germany) mounted on an Axio Observer D1 (Carl Zeiss, 
Oberkochen, Germany) inverted optical microscope (Figure 3.3). Following a well-
established methodology120,195,196, a drop of the sample solution (20 µl) was 
deposited on cut muscovite mica mounted on glass slides. The samples were 
adsorbed, rinsed with deionized water to remove salts and dried under a mild 
nitrogen flow before AFM imaging.  
Images have been acquired in both air and liquid in intermittent contact 
mode, using rectangular silicon cantilevers (TESPA, Bruker, MA, USA) with nominal 
spring constant 42 N/m, resonance frequency 320 kHz, and a tip with curvature 
radius 8 nm, for imaging in air (Figure 3.4 a, b), and triangular silicon nitride 
cantilevers (DNP, Bruker, MA, USA) with nominal elastic constant of 0.24 N/m, 
resonance frequency of 64 kHz, and a tip with a typical curvature radius of 20-60 
nm, for imaging in liquid (Figure 3.4 c, d).  All images were acquired as 512 x 512 
pixels images with a scan rate between 0.6 and 1.0 Hz. 
 
Figure 3.4 | AFM cantilever. (a) Rectangular silicon cantilever for intermittent 
contact imaging in air. (b) Silicon tip of cantilever in a. (c) Triangular silicon nitride 
cantilevers for imaging in liquid. (d) Silicon nitride tip of cantilever in c. 
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3.8 - Stimulated Emission Depletion Microscope   
Commercial Leica STED continuous wave gated microscope (Leica TCS SP5 
gated STED-CW, Leica instrument) has been used. STED Images have been 
collected by a Hybrid detector in the spectral range 470-520 nm171,197. We have 
used an HCX PL APO CS 100x 1.4NA oil objective (Leica Microsystems, Mannheim, 
Germany) and a scan speed of 1000 Hz for 1024 pixel per line with a 32-line 
average and a time-gated detection of 1.2 ns. The selected dye was ATTO 488 for 
insulin and HiLyte Fluor 488 for Aβ measurements, which are suitable for 488 nm 
excitation and 592 nm depletion wavelengths. 
3.9 - Correlative AFM/STED  
A NanoWizard II AFM head (JPK , JPK Instruments, Berlin, Germany) was 
mounted on a commercial Leica STED-gCW microscope, described above (Figure 
3.5a). The optical microscope stage was exchanged with an AFM compatible stage 
(JPK Instruments, Berlin, Germany) (Figure 3.5a inset), which features minimum 
Figure 3.5 | Correlative AFM/STED setup (a). NanoWizard II AFM stage and head 
in the inset. (b) Images of the same area can be acquired in different modes. The 
excitation and depletion lasers arrive from below (inverted optical microscope). The 
confocal and STED images are acquired in fluorescence, while the AFM probe is reaching 
the sample from above, providing a 3D topographical view at high resolution. 
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mechanical coupling of noise to the AFM cantilever. This procedure is made simple 
by the availability of suitable mountings for microscope commercial models. The 
overlay between AFM and STED images (Figure 3.6) was performed by using the 
Direct Overlay software (JPK Instruments, Berlin, Germany).  
Direct overlay requires an image calibration file created for an objective 
and field-of-view from an image sequence of AFM movements. In detail, this 
overlay image is a grid of at least 9 points which nonlinearly shifts, rotates and 
stretches the optical image to correct for all possible optical aberrations. The AFM 
software makes this grid from sequential reflection images of the tip’s actual 
movement in specific piezo positions with a finite pixilation and scan size. The grid 
has been done for a 30 µm x 30 µm, shown in Figure 3.6b and the AFM software 
visualizes the respective overlay of AFM images on 25 µm x 25 µm inside this 
calibrated area.  
The correlative images and the level of co-localization between AFM and 
optical images is calculated by using the colocalization function of ImageJ 
(Bethesda, USA)198,199 and deriving the ratio of colocalization. An example is shown 
in Figure 3.7. In particular, the Colocalization Threshold plugin was employed. The 
threshold was automatically determined by the software, by using the Costes 
autothreshold method200. 
Figure 3.6 | Direct overlay procedure. Panel a shows the total overlay 
procedure. In the first row of this panel, we show a cartoon of the collected optical 
image with inherent aberrations, AFM and the corrected image (Image modified from 
ref. 191). Second row depicts the direct overlay software, which calibrates the pictures 
and makes a grid automatically. The panel b shows the reflection images made on a 30 
µm x 30 µm of optical field of view by moving the tip in 25 µm x25 µm regions in order 
to calibrate this area using 9 points as shown. 
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All the correlative images of insulin samples were acquired in liquid 










Figure 3.7 | Insulin fibril 1:19 dye-to-protein ratio. AFM (a), Confocal (b) and 
STED (c) were analysed by using the Colocalization function by ImageJ (NIH, Bethesda, 
MD, USA). The ratio of colocalization is the ratio between the number of colocalized 
pixels (white pixels in d and e) and the total number of pixel that composed the fibrils in 
the AFM images. 
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Chapter 4  
Characterization of misfolded protein 
aggregates by AFM/STED correlative 
microscopy 
 
4.1 Amyloid fibrils from Insulin 
In this study, as it was already said, bovine insulin has been chosen since 
the structure of insulin fibrils is well known, as well as the number of monomers 
that are present in a unit length of an insulin fibril130. 
Aggregation kinetic was monitored by means ThT assay, to support AFM 
data. Numerous studies have been performed to investigate the physico-chemical 
and spectroscopic properties of ThT upon binding and it’s the binding 
mechanism201. Nielson et al. reported that ThT did not affect the kinetics of insulin 
fibril formation at 60°C124, but other study suggest ‘increasing the ThT 
concentration results in a slightly slower fibrillation process’202. Xue et al. 
compared β2-microglobulin fibrillation in the presence and absence of ThT and 
concluded that ThT has no significant effects on β2-microglobulin aggregation203. 
Regarding Aβ1-40 aggregation experiments, D’Amico et al. suggest that ThT 
promotes Aβ1-40 aggregation201. All these studies reported above and others, 
showing as the changing, in the presence of ThT molecules, during the amyloid 
formation process are concentration-dependent and different for protein 
species44. 
The AFM is considered a primary technique in the study of amyloid fibrils 
and aggregates in vitro, taking advantages of label-free ability, and it has been 
extensively utilized in the last decade195,204–206. The greatest achievement of the 
AFM is the possibility to study proteins in different environments and enabling the 
visualization of dynamic events like the nucleation and fibril formation and 
aggregation. The AFM can take images in solution at distinct time points as well as 
generating time-lapse images about the initial steps of amyloid formation like seed 
formation and about growing fibrils and about the development of matured 
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aggregates. With this technique is possible to study the rates of fibrillogenesis, as 
well as mapping the progression of variations in morphologies and the 
development of structural hierarchy. Furthermore, events can be studied under 
conditions close to the native physiological state207. 
In the last decade a new class of far-field microscopy, SR optical 
microscopy, described in chapter 2, gave new impetus to the investigation of 
nanometric structure, e.g. amyloid aggregates94,208–210,. SR techniques are 
fluorescence microscopy modes, based on the use of fluorescent molecules. Ideal 
molecular dyes must provide high specificity, brightness, and stability. While the 
two former properties are mostly related to the molecular structure of the 
fluorochrome itself, the specificity depends on the method used to recognize and 
bind a particular molecular target211. Furthermore, the influence of the 
fluorescent dye on the biological processes under investigation should be minimal. 
In particular, covalent fluorescent labeling is a procedure commonly applied in 
vitro212. The fluorophores employed for covalent labeling are small molecules 
(<1kDa) and are widely used in the study of dynamic processes of inter-molecular 
interaction. In spite of this, previous reports highlighted that covalent linkage of 
fluorophores can affect the visualization, dynamics and/or biological properties of 
molecular system213–215. However, it is not trivial to have a direct and unambiguous 
assessment of the efficiency and homogeneity of the labeling, as well as on the 
influence that the fluorescent tag has on the molecular activity. 
The work described here as well as the one illustrated in the next chapter 
is addressed on the correlation of SR fluorescence microscopy and label-free AFM 
as a means to study the aggregation process of a non-pathological protein, insulin 
from the bovine pancreas covalently labeled with NHS-dye fluorophore. These 
results demonstrate that the integration of AFM with super resolution 
fluorescence microscopy can be used to validate the results deriving from 




4.1.1 – Insulin fibrillation Kinetics 
Variations of ThT fluorescence signal over time from insulin solution 
containing ThT at 100 Μm concentration were measured, displaying a sigmoidal 
behaviour which is typical of amyloid aggregation kinetics for insulin samples in 
analogous conditions (Figure 4.1). The twofold molar excess of ThT is used to 
ensure saturation of the binding sites. 
 
ThT data show the three main steps occurring in the fibrillation process. As 
it is evident, lag phase lasts for about four days followed by an elongation phase 
that reaches the plateau in eight days. 
Aliquots of insulin-HCl solution were taken at different times to be 
investigated by AFM, and stored at 4 °C in order to slow down the aggregation 
process. Concentration and temperature are the two parameters that influence 
the rate of fibrillation. Five aliquots were extracted during the lag-phase, lasted 
four days, in which prefibrillar aggregates and few small protofibrils are formed. 
Figure 4.1 | Thioflavin t kinetic. Time course aggregation of a 50 μM solution of 
insulin at 60 °C, monitored by ThT fluorescence increase (ThT 100 μM). Emission 
wavelength: range 470-540 nm; excitation wavelength: 450 nm; slit width: 1nm. 
Aliquots of 50 μL of solution were taken away at different time processes. The points 
indicate the aliquots extracted in time and the corresponding ThT normalized value. 
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The other two aliquots correspond, respectively, to the elongation phase, in which 
protofibrils grow, and to the final plateau, characterized by the presence of 
mature fibrils. Repeatability of the sigmoidal behaviour has been verified by 
conducting a triplicate monitoring of the aggregation process. 
  
4.1.2 – AFM characterization of label-free Insulin 
aggregates 
AFM was used as a consolidated technique to follow the aggregation of 
insulin and to characterize the morphology of the fibrils. Insulin solution was 
diluted 100 times with deionized water, 20 μl aliquots were deposited on freshly 
cleaved mica substrate for AFM measurement. As reported in the sample 
preparation section the dilution of the samples with water immediately quenches 
the aggregation process, and the dry conditions prevents further unspecific 
aggregation. The corresponding topographies are shown in Figure 4.2. At the 
beginning of the lag-phase (time 0 – Figure 4.2 a) only small species are present, 
sizing few tens nanometers with a thickness (height) of less than 1 nm. As 
Figure 4.2 | AFM images of unlabeled insulin aggregated species sampled at 
different instant of kinetic and desiccated on mica. a: t= 0; b: t= 3 days; c: 4 days; d: t = 6 




aggregation goes on (time 3 days – Figure 4.2 b), larger globular aggregates and 
few protofibrils form, characterized by a lateral size ranging from 20 to 80 nm and 
a thickness of few nanometers. The elongation start in 4 days of incubation (Figure 
4.2 c), a few small fibrils are present, with a length ranging from 500 nm to 2 µm 
and around 5 nm in thickness. In this part of fibrillation, short fibrils replaced 
prefibrillar aggregates.  
The amount of fibrils increase during the elongation step (Figure 4.2 d, e). 
Mature fibrils appear in the last part of the kinetics (Figure 4.2 f). The process 
reaches equilibrium when most soluble proteins are converted into fibrils, in terms 
of ThT-kinetic is referred to the last part of the elongation phase. The AFM images 
show mature fibrils with a length of several microns and a relatively small 
diameter. In the lateral dimension, the fibrils show a variable size, ranging from 30 
to 80 nm. Unlabeled fibrils have a height of 5.6±1.7 nm. AFM images support 
morphologically the general properties of amyloid insulin structure. In Figure 4.3, 
an investigation at a larger resolution of mature fibrils to highlight characteristic 
features slightly evident in fig. 4.2 e and f.  
Figure 4.3 | AFM image of mature insulin fibrils. (a) Overview of preformed 
insulin in water diluted 100 times (scale bar: 500 nm). (b) Details of structure (scale bar: 
200 nm) and (c) relative profile. Z-range: 15 nm. 
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In Figure 4.3a is clearly noticeable some characteristic traits of the mature 
amyloid fibrils, i.e. the tendencies to bend, twist, and agglomerate. Moreover, in 
Figure 4.3b is visible the classical helix structure: parallel tubular fibers, twisted 
ribbon like structures60. 
 
4.1.3 - AFM characterization of ATTO 488-Insulin 
aggregates  
 ATTO 488 with NHS-esters, for coupling to primary amines on the proteins, 
has been used. Monomeric bovine Insulin present three possible -NHS binding site 
Figure 4.4 | ATTO 488-Insulin 1:19 dye to protein ratio aggregated by AFM. The 
images sampled at different instant of kinetic: (a) 0 day, (b) 6days, (c) 12days (d) 14days. 
Scale bar: 2 µm. Z-range: 7 nm (a, b), 15nm (c, d). 
69 
 
exposed from the structure, two of which concern the strands N-terminus and one 
from a Lysine group on the B-chain. 
The hydrophilic nature of ATTO labels minimizes the risk of interference 
with the protein polymer self-assembly216. Labelling was done preferentially at the 
N- terminus by means of a judicious choice of the reaction pH, using phosphate 
buffer, as described in Methods section. Moreover, in order to have an optimal 
labeling ratio for SR technique, the different ratio between the fractions of labeled 
relative to unlabeled protein were used. Higher labeling density would 
compromise resolution217 and mainly might potentially lead to steric interferences 
of the dye with the fibrils. 
Three dye to protein ratio (i.e., labeled:unlabeled insulin) were tested: 
1:19, 1:99 and 1:499. AFM was used to characterize morphologically the formed 
structure and to verify that the presence of the dye was not precluding then 
formation of the fibrillary aggregates. Following the procedure described 
previously, few microliter of 1:19 labelled insulin was imaged at 0, 6, 12, 14 days 
of incubation time (Figure 4.4). A large number of long unlabelled insulin fibrils 
(with a thickness of 5.6±1.7 nm) at time 6 days (as is shown in Figure 4.2d) are 
displayed. However, AFM image of 1:19 labelled insulin sample at the same time 
(Figure 4.4b) reveal the presence of larger globular aggregates and small 
protofibrils. At the concentration considered, the kinetics of aggregation appear 
slightly delayed by the presence of the fraction of labelled monomers.  
Figure 4.5 | Insulin aggregation in three dye to protein ratio. AFM images 
performed after 10 days incubation in denaturing conditions. (a) 1:19, (b) 1:99, (c) 1:499. 
Scale bar: 1 µm. Z-range: 10 nm 
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Fibrils have a variable length, and the thickness is slightly affected by the 
presence of the dye. In Figure 4.5 are shown, in sequence, the morphologies of 
the three different concentrations. In particular, the mean thickness are: 6.3±2.7 
nm for 1:19 samples (Figure 4.6), 7.5±2.5 nm for 1:99 and 7.6±2.5 nm for 1:499. In 
lateral dimension is possible to observe ranging from 50 to 100 nm. On the other 
hand, the apparent lateral dimension of all AFM-imaged objects are 
overestimated as a result of the influence of the geometry of the probe tip, with a 
finite size, that is in the same order that a protein molecule218,219. The knowledge 
of the approaches in both measurement and data analysis when using AFM 
technique are essential for the correct interpretation of surface topographic 
features. 
 
A qualitative evaluation of fibrils shape 
In this section, I intend to give a brief insight for the characterization of 
protein aggregates structure via AFM. Concerning to handling details, one of the 
most important factors to take into account is the AFM tip. In fact, tip geometry 
can give overestimation the size of the sample, while it does not affect the height 
Figure 4.6 | AFM image of mature insulin fibrils labeled 1:19. (a) Overview of 
preformed insulin in water diluted 100 times (scale bar: 1 µm). (b) Details of structure 
(scale bar: 200 nm) and (c) relative profile. (z-range: 10 nm). 
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measurements. The major effects with regards to tip geometry are those leading 
surface feature broadening as a result of tip curvature's radius being, in this 
specific case, larger than the size of features. During the study of fibril morphology, 
several factors contribute to define the apparent fibril size and shape. In particular, 
the measured fibril width appears much larger than the real fibril size as a result 
of, so-called, ‘tip-broadening’ effects (Figure 4.7).  
Here we roughly consider the fibrils structure as a cylinder, with a circular 
cross-section, therefore the apparent width (W’) is related to the height (h) 
according to the equation,  
𝑊′ =  √8𝑅ℎ 
  
,where R is the radius of curvature of the tip and h the measured 
thickness220. With the values of height above reported and considering the 
nominal R of the tip employed in this work we found that insulin fibrils are 
significantly flattened, likely due to the interaction and binding at the substrate.  
Figure 4.7 | The lateral broadening effect led by the tip size. (a) AFM image in dry 
condition of insulin fibrils structure (Scale bar: 100 nm. Z-range: 10 nm). (b) The profile 
cross-section indicate a height of 4 nm and a length of 30 nm. (c) Schematization of 
broadening effect in AFM image due to tip size effect. 
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In particular, the mean value of W/W’, where W is the measured fibril 
width, is 1.7±0.5 in 1:19 samples, 2.6±0.6 in 1:99, 2±1.1 in 1:499, and 1.5±0.4 in 
label-free insulin. 
 
4.1.4 - AFM/STED on Insulin aggregates 
Correlative AFM/STED technique has been applied in the study of mature 
fibrils, i.e., aggregates after 14 days of incubation in denaturating conditions. 
 In Figure 4.8 is shown an example of image obtained consecutively by 
techniques on the same scan area, highlighting the difference between 
conventional confocal microscopy (in green above) and STED microscopy (in green 
below), and showing the overlap with AFM (red hot colour).  
 
Figure 4.8 | Correlative technique on amyloid fibrils from bovine insulin in 1:19 
dye-to-protein ratio. The STED and Confocal images are overlaid with AFM topography. 
Scale bar: 1 µm. 
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The resolution of the STED microscopy image is significantly enhanced with 
respect to the confocal microscopy image. The fibrillar aggregates at the three 
different dye to protein ratio (called 1:19, 1:99, 1:499 in the following) were 
imaged, following the procedure described in the Methods section.  
SR fluorescence images acquired on the 1:19 sample (Figure 4.9 b, d) show 
a significant presence of unlabeled fibrils, detectable only by using AFM (Figure 
4.9 a, c). Only a fraction of the fibrillar aggregates is displayed in the optical image. 
In particular, some long fibrils are completely missing (white arrow in figure 4.9), 
indicating that the labeled monomers were not taking part in the formation of this 
aggregates. In addition, a heterogeneous distribution of the dye-insulin molecules 
led to the formation of two other species: aggregate entirely fluorescent 
(continuous distribution of fluorophores) and aggregate not homogenous 
fluorescent (discontinuous distribution of fluorophores).  
Fibrils in which the distribution of the fluorophore is discontinuous (white 
arrow in Figure 4.10) have a homogeneous thickness, supporting the idea of a 
regular distribution of protofilaments along the fibrils and, roughly, a same 
amount of monomers per unit length along the whole fibril. 
Figure 4.9 | ATTO 488-Insulin fibrils 1:19 images. AFM (a, c), STED microscopy 
(b, d) and the correlative images obtained by c and d (e). The ratio of co-localization in 
this particular field of view is indicated by the histogram (inset e). Scale bars: (a, b) 5 µm, 
(c-e) 2 µm. Z-range: (a, c) 5 nm. 
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The ratio of co-localization between AFM and STED images is 0.25 for this 
specific field of view. An analysis of 10 images acquire from samples derived from 
3 different preparations indicates a value of correlation of 0.42±0.11.  
The same experiment was repeated on 1:99 (Figure 4.11 a-c) and 1:499 
(Figure 4.11 d-f) samples - 3 preparations per each sample. As expected, the 
correlation between the AFM and STED images decreases at lower dye to protein 
ratio, and the ratio of colocalization is 0.29±0.07 (1:99, n=10) and 0.19±0.09 
(1:499, n=10).  
 
 
Figure 4.10 | Detail of insulin 1:19 fibrils in AFM (a), STED (b), Confocal (c). (d) 
AFM profile comparison of the same fibril displayed a not continuous distribution of 





Figure 4.11 | Insulin fibrils obtained from 1:99 (a-c), and 1:499 (d-f) dye to 
protein ratio.  AFM images (a, d), STED microscopy images (b, e) and correlative images 
obtained by the previous (c, f). Several fibrils are totally unlabeled. This result resembles 
the one obtained at a dye to protein ratio of 1:19. The ratio of colocalization is shown 
by the blue bar in the inset. Scale bar: 1 µm. Z-range: (a, d) 10 nm. 
76 
 
4.2 - Characterization of Aβ aggregation  
Biophysical techniques can be used to study protein aggregation and give 
information about, for instance, aggregation kinetics221,222. These techniques 
generally average over a large number of aggregating molecules and cannot be 
used to read out the length or shape of individual fibrils. On the other hand, high-
resolution microscopy methods such as AFM and EM have been applied to 
studying fibril growth with resolutions lower than 1 nm60,223,224. Moreover, SR 
fluorescence microscopes were applied in the study of the molecular mechanism 
associated with misfolded protein diseases. In particular, Direct-STORM technique 
was used to investigate the aggregation of Aβ both in vitro and in situ, offering a 
useful approach in the study of the morphological differences between the species 
217. By using two-color dSTORM, the polarized elongation of Aβ1-42 fibrils was also 
demonstrated225. Immunolabeled tau filaments from brain sections were imaged 
with a resolution of 77 nm by using STED microscopy152. In a recent study, the 
preferential localization of γ-secretase in the presynaptic and postsynaptic 
compartment has been characterized by STORM and STED microscopy226. In the 
field of Parkinson’s disease, amyloid fibrils from α-synuclein were imaged with an 
unprecedented resolution by using binding-activated localization microscopy 
(BALM)227. Two-color d-STORM has been employed to study the elongation of 
preformed α-synuclein fibrils, providing new insights into the role of seeding in the 
fibrillogenesis228. Finally, the fibrillation of human lysozyme, involved in a fatal 
form of hereditary systemic amyloidosis was characterized in details229.  
The molecular mechanism involved in cross-β structure proteins 
aggregation into fibrillar structures is nowadays an open question. In-depth 
analysis of the dynamics of these processes can lead to a better understanding of 
the cause of these diseases and assist progress in the search for therapeutic 
intervention230. 
The workplan of this section is to use of the correlative technique AFM-
STED, to analyze the eventual affection induced by the presence of a fraction of 
fluorescent Aβ molecules on the aggregation process. We used a largely employed 





4.2.1 – Aβ fibrillation Kinetics 
Aβ1-42 and Aβ1-40 aggregation kinetics was investigated using ThT assay. 
Dilution of ThT stock solution was done in PBS buffer at the final concentration of 
50 µM and used with 25 µM of Aβ protein at 25°C.  
The fluorescence was measured using an excitation of 450 nm and an 
emission of 482 nm. Aliquots of Aβ-Tht solution, immediately after mixing, were 
investigated directly by spectrofluorometer over 4 hours. The kinetic course graph 
in Figure 4.12, with the characteristic phase of amyloid aggregation, shows that Aβ1-
42 is slightly faster than Aβ1-40, with a smaller Lag-phase. 
 
4.2.2 - AFM characterization of Aβ1-42 and Aβ1-40 fibrillar 
aggregates 
The aggregation of Aβ1-42 was induced using standard protocol proposed in 
the literature31,194 and described in Chapter 3. The characterization of the initial 
state of the aggregation was made to exclude the presence of pre-existent fibrillar 
aggregates that could induce important artefact in the analysis.  
Figure 4.12 | ThT fluorescence intensity kinetics of Aβ. Time course aggregation of 
a 25 μM solution of Aβ1-40 (a) and Aβ1-42 (b), monitored by ThT fluorescence increase (ThT 
concentration was 50 μM). Emission wavelength: 482 nm; excitation wavelength: 450 nm; 
slit width: 1nm.  
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AFM images acquired just after the resuspension of the lyophilized peptide 
in the aggregation medium are shown in Figure 4.13 and are indicating the 
presence of a monodisperse distribution of globular aggregates.   
The dynamic light scattering (DLS) confirm the data with a mean size for 
Aβ1-42 of 2.0±0.4 nm and for Aβ1-40 of 2.4±0.3 nm. 
AFM images support ThT measurement, after 1 day of aggregation the 
fibrillar proteins are present (Figure 4.14) and completely formed in branched 
fibrils. 
Figure 4.13 | AFM images of amyloid-β peptides just after resuspension of 
the lyophilized peptide in the aggregation medium. Aβ1-42 (a) unlabeled, (b) 1:19, (c) 
1:99, (d) 1:499. Aβ1-40 (e) unlabeled and (f) 1:19. Scale bar: 1 μm. Z-range: 10 nm. 
Insets scale bars: 200 nm. Prefibrillar aggregates are not present at the beginning of 
the aggregation process.   
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4.2.3 - AFM/STED on Aβ1-42 and Aβ1-40 aggregates 
The well-established correlative method tested on insulin aggregation, has 
highlighted a new and important scenario about aggregation studies. In order to 
have a more general view and to extend the result to a pathological peptide 
synthetic Aβ1-42/Aβ1-40-HiLyte Fluor 488 (HF488) has been used. Correlative 
AFM/STED technique has been applied on mature fibrils, i.e., aggregates after 1 
day of incubation at 37°C. Following the same procedure explained for insulin, the 
HF488-aggregates was investigated in three different ratios between the fractions 
of labeled relative to unlabeled protein: 1:19, 1:99, 1:499. The correlative images 
indicated the presence of different types of aggregates (Figure 4.15); with a 
significant unlabeled fraction of fibrils already present at a dye to protein ratio of 
1:19 (Figure 4.15 a-c). The correlation between AFM and STED images, i.e., the 
Figure 4.14 | Amyloid β fibrils. AFM was used to follow the aggregation of Aβ1-
42 and to characterize the morphology of the fibrils after 1 day of aggregation. (a) 
Unlabeled, (b) 1:19, (c) 1:99, (d) 1:499. Aβ1-40 (e) unlabeled and (f) 1:19. Scale bar: 1 µm. 
Z-range: (a) 10 nm, (b, c, d, e, f) 20nm.  
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population of fibrils that are visible in fluorescence microscopy, decreases 
at lower dye to protein ratio: 0.45±0.13 (1:19), 0.26±0.11 (1:99), and 0.16±0.04 
(1:499).  
 
These results, derived from two different preparations, and from a total 
number of 15 images per each sample, are summarized in discussion section 
(Table 4.1). Furthermore, these results have been confirmed on HF488 Aβ1-40, 
analysing 22 different images from two different preparations at 1:19 dye-to-
protein ratio. The presence of a significant population of unlabeled fibrils is 
evident in Figure 4.16 a-c.  
Figure 4.15 | Amyloid aggregates from HF488 Aβ1-42. Different concentrations of 
fluorescent peptides were present. The dye to protein ratios are (a-c) 1:19, (d-f) 1:99, (g-
I) 1:499. Also at the higher dye to protein ratio (a-c) some fibrils were not displayed by 
fluorescence images (e.g., see the withe arrows). Scale bar 2 μm. Z-Range (a, g) 10 nm, 




4.2.4 - Characterization of immunolabeled Aβ1-42 
aggregates 
Amyloid fibrils from Aβ1-42 were labeled via indirect immunolabeling, 
following a well-established procedure (See Chapter 3). After the conjugation with 
the fluorescent secondary antibody, we found that all the fibrillar aggregates 
displayed by AFM were also visible in the STED image. As a consequence of this, 
the correlation between the AFM and STED images (Figure 4.17) is very high for all 
the images acquired (n=12) and for the two preparations.  
The level of co-localization between AFM and STED images has been 
quantified to 0.92±0.05. The typical cross-section of the fibrils, measured by AFM 
(Figure 4.17 a, d), is significantly increased as a consequence of a massive binding 
of antibody molecules at the fibril surface, with a mean height value of 20.4±7 nm. 
This indirect proof of the presence of the molecular dyes is a final example of the 







Figure 4.16 | AFM/STED on HF488 Aβ1-40 aggregates. Fibril imaged by AFM (a) 
and STED (b). The overlapped image (c) in which the green color represent STED fibrils, 
red color AFM fibrils and in white color the ratio of co-localization. The dye to protein 




4.3 - Discussion 
Amyloid aggregates derived from insulin and two different alloforms of β-
amyloid peptides, Aβ1-42, and Aβ1-40 were images by correlative AFM-STED 
microscopy. The aggregation started from solutions of mixed unlabeled and 
labeled proteins/peptides at different dye to protein ratio (1:19, 1:99, 1:499). The 
dye to protein ratio of 1:19 was chosen following well established methods and 
largely employed231–233, while 1:99 and 1:499 were used as a control, in order to 
evaluate how the presence of fluorescent aggregates rescale with the 
concentration of the dye. Insulin was labeled by covalently binding a fluorophore 
at the free amine groups, while fluorescent Aβ1-42 and Aβ1-40 presented a single 
fluorophore at a terminal group and was purchased by an external company. In 
both the cases, we found that, at all the three dye to protein ratio under 
Figure 4.17 | Amyloid aggregates formed from Aβ1-42 in the absence of 
fluorescent monomers and subsequently labelled via indirect immunolabeling. All the 
features displayed in the AFM images (a, d) are also visible in the STED images (b, e) and 
are colocalized (c, f). Interestingly, the fibrils size, measured by AFM, is larger with 
respect to the unlabeled fibrils, confirming the presence of a large amount of antibody 
on the fibrillar aggregates. Scale bar (a-c) 2 µm, (d-f) 1 µm. Z-range (a, b) 30 nm. Inset 
(f) graph of co-localization   
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investigation, fluorescent fibrils coexist with a significant fraction of aggregates 
that are mainly, or entirely unlabeled.  
Insulin from the bovine pancreas is not an amyloidogenic protein in vivo. 
In particular, we chose insulin since the structure of insulin fibrils is well known, as 
well as the number of monomers that are present in a unit length of an insulin 
fibril130 . From Small Angle Scattering experiments, it was calculated that an insulin 
fibrils with a circular cross-section of 6 nm in diameter is formed by 7 
protofilaments and the number of monomer per unit length was calculated. 
Comparing this model with the morphological features of our insulin fibrils 
(average thickness and aspect ratio is reported in Insulin section) and with the 
assumption of an indistinct aggregation - in which fibrils are the result of the 
stochastic assembly of labeled and unlabeled monomers - we deduce that at least 
1 labeled molecules every   ̴ 6 nm along the fibril axis must be expected in 1:19 
samples, 1 every 30 nm in 1:99 samples and 1 every 150 nm in 1:499 samples. 
Considering this rough estimation, if the labeled monomers take part to the 
aggregation process stochastically, considering the resolution achieved in our 
experimental conditions, the fibrils must appear homogeneously and entirely 
Figure 4.18 | A stochastic aggregation of the labeled/unlabeled peptides should 
bring to the formation of uniformly labeled fibrils. Our experiments indicate a different 
scenario where just a fraction of the fibrils has a labeled component. Other fibrils, dark 
in the STED analysis, are unlabeled. These two products are the results of different 




fluorescent upon STED microscopy visualization, at least in the case of 1:19 and 
1:99 samples (Figures 4.9, 4.11a-c). The presence of a large population of 
unlabeled fibrils indicates the coexistence of distinct aggregation pathways, some 
of them allow the contribution of the labeled peptide in the formation of 
aggregates, and the others preclude this contribution (Figure 4.18).   
The presence of directly labeled monomers is not only slowing the kinetics 
of the aggregation of insulin, but is favoring the coexistence of the different 
aggregation pathways bringing to two distinct final products: labelled and 
unlabeled fibrils. We pointed out that the presence of these two species of 
aggregates can be evinced only by applying a couple AFM-fluorescence 
microscopy correlative technique, but we also noted that only super-resolution 
microscopy is providing the sufficient capability of discerning between different 
filaments that are tightly packed in a confined space. 
The same procedure has been applied to the Alzheimer’s associated 
peptides Aβ1-42 and Aβ1-40, demonstrating that the phenomenon described in 
details for insulin is general in the process of aggregation of misfolded proteins. 
Furthermore, unlabeled aggregates are present also when the peptides are 
labeled with a  single dye at the N-terminus, a part of the polypeptide chain that 
has been classically considered as scarcely relevant in fibrillation processes225,233. 
In Table 4.1, an overview of the data obtained for the different peptide species 
and dye to protein ratios. The colocalization values (the ratio between the number 
of co-localized pixels and the total number of pixel that composed the fibrils in the 
AFM images) show a lower amount over the decreasing of the dye, how we 
expected, but also very similar values among the different species for each 
concentration. Suggesting a similar behavior in the aggregation process in 
presence of the dye molecule of insulin and Aβ peptides. 
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By using a standard indirect immunolabeling method, we have been able 
to display the entire population of fibrils within the sample, demonstrating that 
the loss of information evinced from directly labeled samples is not related to an 
instrumental limit, but is inherently related to the sample properties. 
 
As a whole, these results indicate that the integration between AFM and 
super-resolution fluorescence microscopy represents not only a complement but 
a fundamental tool to validate the results deriving from fluorescence microscopy, 
and that it can drive the experiments towards more accurate and less invasive 
methods of labeling. AFM-STED microscopy could be a fundamental test in the 
validation and in the quality control of the new dyes employed for the in vitro 









Insulin Aβ 1-42 Aβ 1-40
0.42±0.11 0.45±0.13 0.47±0.04 1:19
0.29±0.07 0.26±0.11 - 1:99
0.19±0.09 0.16±0.04 - 1:499
Table 4.1 | The ratio of colocalization calculated for the different peptide species 





Interaction between plasma membrane 
and amyloid protein 
 
5.1 - Plasma membrane and membrane model  
The membrane of cells is the interface through which all interactions of the 
cell with its direct outer world take place (Figure 5.1). It is a complex structure 
involved in important biological processes, including bidirectional transport of 
molecules and cell-cell communication. The two principal components of 
biological membranes are lipids and proteins, perfectly organized at the molecular 
level in a cell-dependent ratio234. Different kind of lipids composes the membrane 
structure: glycerophospholipids, sphingolipids, and sterols235. However, lipids are 
not uniformly distributed between the two membrane leaflets236–238: 
phosphatidylcholine, which accounts for more than half of phospholipids in most 
of the eukaryotic membranes, is mainly located in the outer leaflet, as well as 
sphingolipids, while phosphatidylserine, phosphatidylethanolamine and 
phosphatidylinositol are predominantly found in the inner leaflet. Cholesterol 
resides for more than 70% in the cytofacial leaflet. Nevertheless, its presence and 
distribution in the exofacial leaflet are fundamental in determining lateral lipid 
organization. 
Figure 5.1 | Schematic representation of plasma membrane.  
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The membrane basic structure consists of a double layer of amphiphilic 
lipid molecules, with the polar parts pointing toward the aqueous medium and the 
hydrophobic moieties facing each other. Plasma membrane, ranging from only a 
few nanometers in thickness, is selectively permeable, generally less permeable 
to large, polar solutes and therefore drugs and biomolecules interacting with the 
cell must first permeate the membrane. 
 
The first modern model was proposed by S.J. Singer and Garth L. Nicolson 
in 1972, called the fluid mosaic model239. The model has evolved somewhat over 
time, but it still best accounts for the structure and functions of the plasma 
membrane as we now understand them. However, this model did not take into 
account a central aspect of the lipid bilayer structure, the lateral organization of 
Figure 5.2 | Phase separation in a supported lipid bilayer containing DOPC, 
Sphingomyelin (SM), Cholesterol and GM1 imaged using AFM. (a) Typical morphology. 
Scale bar: 1.0 µm. (b) Cross section was taken along the white line in a (X axis). The 
difference in height between the two phases is    ̴2.2 nm. Images and plot profile from 
Oropesa et al.78 . (c) Particular view of lipid lα and lo domains. Scale bar: 200 nm. 
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the membrane that is involved in several functions such as signal transduction, 
protein and lipid sorting, and endocytosis. In 1997 it was introduced a new concept 
asserting the not uniformity in the lipid distribution in cell membrane matrix240. It 
is thought that different types of lipids actively phase-segregate, forming distinct 
compartments241, different in composition and physical properties.  
The differential solubility of the plasma membrane, treating the cells with 
a cold detergent, such as Triton-X, was demonstrated242. One of those fractions, 
defined as a detergent-resist membrane, or lipid raft, is enriched in cholesterol 
and sphingolipids243. Lipid rafts are small liquid-ordered (Lα) assemblies of 
sphingolipids, cholesterol and raft-associated membrane proteins that diffuse 
within the liquid disordered (Lo) lipid membrane. Raft and raft-associated 
membrane proteins have been recognized has the responsible of a growing 
number of physiological and pathological cellular processes and hence our interest 
in them77,78,244. Due to their small size (10-200 nm)245 or to their possible transient 
nature246, direct observation of these structures in the real cell membrane is still 
missing. To test this hypothesis but to avoid the inherent complexity and 
heterogeneity of the cell membrane, a simplified model capable of mimicking the 
behavior of the extracellular membrane have been used to investigate the 
segregation behavior of lipids and different proteins in predetermined lipid 
mixture. Work in this direction has been performed using atomic force 
microscopy77,78,247 (Figure 5.2) and a combination of AFM and fluorescent 
correlation spectroscopy248,249. 
 
5.2 – Alpha-synuclein: structure, functions, and 
interactions 
α-Synuclein is a physiological protein mainly observed in the presynaptic 
terminal of the neurons. Although the function of native α-syn is not well 
understood, studies suggest that it is associated with the synapse and involved in 
synaptic activity, synaptic plasticity, neurotransmitter release, dopamine 
metabolism, synaptic pool maintenance and vesicle trafficking272,273. Disorders 
characterized by α-syn accumulation, Lewy body formation and Parkinsonism (and 
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in some cases dementia) are collectively known as Lewy body diseases (LBD). It is 
considered as a molecular biomarker for the detection of Parkinson disease (PD) 
in its earlier stages274, also present in AD plaques as a non-Aβ component (NAC). 
The molecular mechanism(s) through which α-syn abnormally accumulates and 
contributes to neurodegeneration in these disorders remains unknown.  
 
The human α-syn protein is made of 140 amino acids with three domains: 
an N-terminal lipid-binding region, a hydrophobic central domain and a C-terminal 
acidic tail (Figure 5.3). α-Syn can be present as an α-helix structure in association 
with phospholipids (lipid-binding region) or an unfolded conformation in the 
cytosol, suggesting that it plays specific roles in different cellular locations based 
on its dynamic structure275. The N-terminal domain of α-syn is a positively charged 
region, containing sequences repeats that are also present in the α-helical domain 
of apolipoproteins (lipid-transport proteins). These repeats are responsible for the 
ability to form α-helical structures and therefore important in α-syn-lipid 
interactions. The core region of α-syn, known as NAC, is particularly rich in 
hydrophobic residues and makes up the core region of amyloid fibrils as it forms 
cross-β structure276,277. The C-terminal domain of α-syn is present in a random coil 
structure due to its low hydrophobicity and high net negative charge. In vitro 
studies have revealed that α-syn aggregation can be induced by lowering pH or by 
truncations of the C-terminal278,279. α-Syn can be found both as an intrinsically 
disordered peptide in the cytosol but also with an α-helical conformation when 
Figure 5.3 | Primary and secondary structure of α-syn. To right shows the three 
main domains of α-syn. The N-terminal is an amphipathic domain that contains the three 
point mutations (white bars) linked to the autosomal dominant form of PD. The central 
region is a highly hydrophobic domain that was originally identified in patients with AD or 
LBD, which is the precursor of the non-amyloidogenic component of the extracellular 
senile plaque (NAC), which promotes the protein aggregation. The C-terminal domain has 
an acidic character, which possesses anti-amyloidogenic properties. 
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associated to lipid membranes. It is therefore suggested based on its dynamic 
structure, to play specific roles in different cellular locations. 
Amyloid protein and lipid membranes interaction is of critical importance 
in biology, potentially associated with toxicity and propagation of Parkinson´s 
disease. Several techniques, such as spectroscopy, AFM, and protein chemistry 
have been used to address and investigate the influence of lipid bilayer model, 
that mimic the outer leaflet membrane, on the aggregation of α-syn280. On the 
other hands, a well-characterized lipid composition and its relative SLB, for AFM-
α-syn interaction studies, that simulate the cytoplasmic leaflet of the membranes 
is not still available.  
Understanding the nature of the α-syn-membrane interaction, how it is 
involved in the toxicity may inform future studies aiming to develop therapeutic 
prevention and intervention. 
 
5.3 - Materials and Methods 
The experimental works described in this chapter are based on in situ AFM 
application, previous described in chapter 2. The main aim is related to the 
characterization of the affections induced by α-syn aggregates on Solid-supported 
Lipid Bilayers (SLBs). Here, it has been investigated on two different SLBs 
composition: a well-studied bilayer that mimic the outer (extracellular) leaflet 
(following the protocols previously defined in our lab78),  and a new more complex 
bilayer model that simulate the inner leaflet (cytoplasmic) of the membranes. I 
will describe the procedures used in supported lipid bilayers preparation and the 
potentialities of AFM in the study of these model systems. 
 
5.3.1 - SLB preparation 
SLBs used in the experimental work were prepared employing vesicle 
fusion technique on mica substrate. Vesicle fusion consists in the deposition of a 
large unilamellar vesicles (LUVs) suspension onto a hydrophilic substrate: vesicle 
adsorption and spreading on the surface may lead, under specific conditions, to 
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bilayer formation (Figure 5.4). LUVs solution has been made at ‘Italian Institute of 
technology’ in Genova by Barbara Salis, following a standard protocol74.  
For external leaflet, lipid vesicles are formed by unsaturated 1,2-dioleoyl-
SN-glycero-3-phosphocholine (DOPC), sphingomyelin (SM) (brain, porcine) in a 2:1 
molar ratio, cholesterol (Chol) 1% molar and 5% molar of ganglioside GM1 (brain, 
ovine). At room temperature, each LUVs suspension was diluted 10 times with 
ultrapure water. 40 µL of LUVs suspension 0.1 mg/mL were then administrated to 
freshly cleaved mica, attached to a coverslip slide. Right after, 10 µL of CaCl2 10 
mM were added, in order to trigger vesicle fusion. After a variable resting time, 
preceding the beginning of bilayer formation (indicated by a variation of liquid 
spreading on the substrate), samples were stored at 60°C in a close chamber with 
100% relative humidity (r.h) for 15 minutes. The samples were cooled at room 
temperature and, after 2.0 h, gently rinsed three times with ultrapure water to 
remove excess vesicles from the liquid phase before AFM measurements. The 
surface was kept hydrated during the rinse. 
 
For the inner leaflet preparation was used the same vesicle fusion protocol 
described above. Different lipid compositions were tested to produce inner 
membrane models in order to fabricate a proper and stable SLB by vesicle fusion. 
In particular, the final LUVs composition, in molar ratios, employed for the 
Figure 5.4 | Schematic representation of the vesicle fusion protocol employed 
in this work. 
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experiments is: 45% DOPC, 20% 1,2-diolyeil-phosphatidylethanolamine (DOPE), 
20% SM , 10% 1-palmitoyl-2-oleoyl-SN-glycero-3-phospho-L-serine (POPS) and 5% 
cholesterol. Using this lipid mixture, LUVs were fabricated in PBS 1X. 
 
5.3.2 - Peptide preparation 
Lyophilized α-syn (Sigma-Aldrich, St Louis, MO, USA) was dissolved, at the 
final concentration of 1 mg/ml in ultrapure water. Aliquots of 200 µl were stored 
at -20°C. Oligomers were prepared, starting from frozen aliquots, sonicated for 5 
min, diluted at the selected concentration in ultrapure water and used for SLB 
interaction studies. Regarding the external leaflet, a 1nM concentration of α-syn 
was used, while for the inner bilayer increased concentration ranging from 20nM 
to 200nM.  
 
5.4.3 – AFM on Supported Lipid Bilayer  
AFM measurements were performed by using the setup previously 
described in Chapter 3. V-shaped DNP silicon nitride cantilevers (Bruker, 
Massachusetts, US), with a nominal spring constant 0.24 N/m, a resonance 
frequency in air ranging from 40 to 75 kHz, and a tip with typical curvature radius 
Figure 5.5 | Difference in thickness between outer (a) and inner (b) 
leaflet.   
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20-60 nm were used. Before α-syn administration, the morphological features of 
SLBs were evaluated through AFM imaging. The AFM tip was lifted up 100 μm from 
the sample, the oligomer was administered, to the bilayer, and let incubating for 
10 minutes before further measurements. AFM imaging on SLBs is performed in a 
water environment to preserve the lamellar configuration of the bilayer. AFM 
images are acquired both in intermittent contact mode. In all the cases, the 
amplitude setpoint was kept above 70% of free oscillation amplitude to prevent 
possible damages to the sample. The determination of the difference in thickness 
between the ordered (Lβ) and disordered (Lα) lipid phases (ΔZ) was determined by 
analyzing image height distributions with the help of the JPK Data Processing 
software (JPK Instruments, Germany). The actual spring constant of each 
cantilever was ascertained in situ, using the thermal noise method. 
 
5.4 - Results 
Cell membranes have complex lipid compositions, including an asymmetric 
distribution of phospholipids between the opposing leaflets of the bilayer. 
Figure 5.6 | AFM images of SLBs sampled before (a-c) and after administration 
of α-syn aggregates solutions (d-f). After 10 min incubation, α-syn induce destabilization 




Although it has been well observed the lipid composition of the outer leaflet of 
the plasma membrane and the formation of Lβ domains, the lipids of the inner 
leaflet remains unknown281.  
It is well known that the lipid composition of outer and inner leaflets of the 
plasmatic neuronal membrane is different282. Both leaflets include 
phosphatidylcholine (PC), sphingomyelin (SM) and cholesterol (ch). In particular, 
the inner leaflet of the cellular membrane is more negatively charged than the 
outer leaflet and, in addition, it is characterized by the presence of 
phosphatidylethanolamine (PE). AFM result to be the most advantageous method 
for the study of the SLB model system, due to the high lateral and vertical 
resolutions. Indeed, it has been widely used to characterize supported model 
membranes283,284, as well as to investigate their interaction with peptides at the 
nanoscale285,286. The unique features of AFM allow the study of the presence of 
different domains in the bilayer, including the difference in thickness between 
coexisting lipid phases. Here, I compared the morphology of the SLBs before and 
after the interaction with α-syn. In Figure 5.5, it is shown a typical bilayer 
morphology with characteristic raft domain for each lipid composition. The first 
morphology shown in Figure 5.2c is related to the microdomains thickness, which 
range from 1 nm to 1.5 nm in the DOPC/SM/ch/GM1 SLB, while for inner leaflet 
(DOPC/DOPE/SM/POPS/ch) less than 1 nm.  
Figure 5.7 | The neural inner plasmatic model membrane 
(DOPC/DOPE/SM/POPS/ch) by AFM. The profile section (with the dark line) below the 
image shows the roughness in the initial stage of the scan session.  Scale bar 1 µm (a, 




The experimental protocol employed in this study, regarding the peptide 
interaction, consisted in administering α-syn aggregates solution to defect-free 
bilayers, incubating for 10 min, rinsing, and checking with AFM to determine 
possible destabilizing effects. The integrity of DOPC/SM/ch/GM1 SLBs has been 
verified with AFM before peptide administration: intermittent contact imaging 
produced typical topography as expected for an intact SLB (Figure 5.6 a-c). In 
addition, the process of bilayer phases formation can be monitored through image 
acquisition at different time intervals after vesicles administration until it reaches 
the complete stabilisation. Images were acquired at 10x10 µm, 5x5 µm and 1x1 
µm. 
 
Right after, SLB has been incubated with aggregates solutions at 1 nM 
concentration, following the procedure described above. In Figure 5.6 d-f it is 
shown the peptide effect obtained, after waiting 10 min, on the bilayer surface. 
Figure 5.8 | AFM Images of α-syn interaction with DOPC/DOPE/SM/POPS/ch 
bilayer. After 10 min incubation time oligomers peptide induced removal of bilayer parts 
and consequent holes formation. (a) 20 nM and (b) 70 nM concentration of α-syn 
deposited. The black line indicates a profile section (showed below). Scale bar 1 µm. Z-
range 10 nm. 
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The results indicate an evident disruptive interaction between α-syn and 
DOPC/SM/ch/GM1 lipid membrane, indicated by the holes formation on the 
surface. This result is in agreement with a large number of literature data51,76–78, 
which identify that low concentration of oligomers peptide induced removal of 
bilayer parts and consequent holes formation. In our experiments it is clear that 
the damage is higher in the fluid domain. 
For the inner leaflet preparation was used the protocol described in 
Methods section. Firstly, it has been tested the stability and the presence of the 
phase on the bilayer. Initially, the lipid segregation within the bilayer appears not 
well define (as it is shown in Figure 5.7 a). After the complete formation and 
stabilization of the order phase domain (Figure 5.7 c), the protein solution has 
been added on the bilayer. I observed that, as expected, the interaction is 
concentration-dependent. The first visible effect on lipid bilayer was observed at 
20 nM concentration of α-syn (Figure 5.8 a), at this concentration the formation 
of holes is evident. Besides, increasing the protein concentration at 70 nM further 
destabilization is obtained (Figure 5.8 b). In Figure 5.8 are reported images of the 
same sample shown in Figure 5.7.  
Also in this second case, the damage is prominently in the fluid phase 
domain, indicating that the mechanical properties of the lipid membrane have a 
central role in the definition of the mechanism of interaction between membrane 
and pathological peptides/peptide aggregates. Furthermore, these results 
indicates that a significant damage of the outer leaflet composition membrane is 
obtained at concentration at least 20 time lower with respect to the membranes 
that simulate the inner composition.  
Studies performed by Barbara Salis in our lab by means of Quartz Crystal 
Microbalance (QCM) confirmed the inner bilayer-protein interaction data 
obtained in this study by AFM.  
These results are preliminary, but in my thesis work, I set the condition for 
the formation of the bilayer that mimic the inner leaflet composition, a 
fundamental step to obtain further consistent and reproducible results. A further 
step in this research activity would be represented by the introduction of some 
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fluorescent components and in a combined analysis by using the integrated 



































My work is focused on the application of advanced biophysical approaches 
to the study of molecular processes involved in protein conformational diseases 
that arise from uncorrected protein folding and subsequent aggregation.  
My work can be divided into two phases. The main part is presented in 
Chapter 4, and regards the study of the anomalous effects induces by the presence 
of fluorescently labeled peptides on the fibrillation process of misfolded proteins. 
The second part, described in Chapter 5, introduces a study on the interaction of 
a particular amyloidogenic peptide, α-syn, and planar supported lipid membranes. 
In particular, I show that the slowing of the kinetics of aggregation, 
detectable with several techniques such as ThT binding, AFM, reported in this 
study and others present in the literature (FTIR, time-lapse) is just an aspect of the 
influence of the labeled monomers on the intermolecular processes. The results 
obtained by applying for the first time correlative AFM-STED microscopy to this 
biological problem revealed the rising of unexpected mechanisms of aggregation. 
I clearly demonstrate that labeled peptides are following only selective 
aggregation pathways, as a result of this, only part the amyloid aggregates, 
generated by the aggregation of a mixture of labeled/unlabeled monomers, are 
fluorescent.  This novel findings generate a warning: fluorescence techniques are 
not able to characterise all the products derived from the in vitro aggregation of 
misfolded proteins. This statement reveals the importance to correlate 
fluorescence data with other derived from label-free techniques. The loss of 
information that is not only affecting the imaging, but also the spectroscopic 
techniques based on the fluorescence of a dye molecule, is suggesting the primary 
role that can be played by label-free techniques. 
We pointed out that the presence of these two species of aggregates can 




These findings, defining a new and not expected scenario, suggested the 
need of new investigations aimed to characterize the physico-chemical properties 
of the two species of aggregates, i.e., fluorescent and non-fluorescent aggregates. 
Furthermore, the analysis should be extended to the bio-activity of the same 
species with a particular focus on their toxicity. 
In Chapter 5, I present a study on the interaction mechanisms of α-syn, a 
peptide related to Parkinson’s disease, and lipid membranes. In particular, the role 
of membrane composition is investigated. I focused my attention on two different 
compositions of lipids, one that mimic the external part of the neuronal cell 
membrane, and a second that resembles that internal leaflet of the membrane. I 
observed that α-syn is able to damage both the model membranes, but 
concentrating its destabilization on the fluid part of the membrane. Furthermore, 
I found that the membranes derived from the external leaflet composition are 
destabilized at a lower peptides concentration. The formation of pore-like 
structure was not detected in my investigation, supporting the idea of a cytotoxic 
mechanism related to membrane disruption. This result suggests a new aspect to 
be considered in the definition of the mechanism of neurodegeneration in 
Parkinson’s disease. The work on the bilayer that mimic the inner leaflet 
composition has to be consider as a preliminary step toward the accomplishment 
of a systematic investigation. However, in my PhD work I set the experimental 
















1. Sipe, J. D. et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification 
of the amyloidosis. Amyloid 21, 221–224 (2014). 
2. Dobson, C. M. Protein folding and misfolding. 426, (2003). 
3. Fink, A. L. Protein aggregation: Folding aggregates, inclusion bodies and amyloid. 
Fold. Des. 3, 9–23 (1998). 
4. Bucciantini, M., Rigacci, S. & Stefani, M. Amyloid aggregation: Role of biological 
membranes and the aggregate-membrane system. J. Phys. Chem. Lett. 5, 517–527 
(2014). 
5. Virchow, R. Ueber eine im Gehirn und Rückenmark des Menschen aufgefundene 
Substanz mit der chemischen Reaction der Cellulose. Arch. für Pathol. Anat. und 
Physiol. und für Klin. Med. 6, 135–138 (1854). 
6. Friedreich, N.; Kekule, A. Zur Amyloidfrange. Virchows Arch Pathol Anat 1859, 16, 
50–65. 
7. Divry, P., and Florkin, M. (1927) Sur les proprietes optiques de l’amyloide, C. R. Soc. 
Biol. 97, 1808–1810. 
8. Cohen, A. S. & Calkins, E. Electron Microscopic Observations on a Fibrous Component 
in Amyloid of Diverse Origins. Nature 183, 1202 (1959). 
9. Stefani, M. & Dobson, C. M. Protein aggregation and aggregate toxicity: New insights 
into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 
678–699 (2003). 
10. Chiti, F. & Dobson, C. M. Protein Misfolding, Functional Amyloid, and Human 
Disease. Annu. Rev. Biochem. 75, 333–366 (2006). 
11. Sambrook, J. & Gething, M. J. Protein folding in the cell. Nature 355, 33–45 (1992). 
12. Brodsky, J. L. & McCracken, A. A. ER protein quality control and proteasome-
mediated protein degradation. Semin. Cell Dev. Biol. 10, 507–513 (1999). 
13. Vendruscolo, M., Zurdo, J., Macphee, C. E. & Dobson, C. M. Protein folding and 
misfolding: A paradigm of self-assembly and regulation in complex biological 
systems. Philos. Trans. R. Soc. A Math. Phys. Eng. Sci. 361, 1205–1222 (2003). 
14. Levinthal, C. Are there pathways for protein folding? J. Chim. Phys. 65, 44–45 (1968). 
15. Dill, K. A. & Chan, H. S. From levinthal to pathways to funnels. Nature Structural 
Biology 4, 10–19 (1997). 
16. Dinner, A. R., Šalib, A., Smitha, L. J., Dobsona, C. M. & Karplus, M. Understanding 
protein folding via free-energy surfaces from theory and experiment. Trends 
Biochem. Sci. 25, 331–339 (2000). 
17. Chan, H. S. & Dill, K. A. Protein folding in the landscape perspective: Chevron plots 
and non-arrhenius kinetics. Proteins Struct. Funct. Genet. 30, 2–33 (1998). 
18. Anfinsen, C. B. Principles that Govern the Folding of Protein Chains. Science (80-. ). 
181, 223–230 (1973). 
19. Fersht, A. R. & Daggett, V. Protein folding and unfolding at atomic resolution. Cell 
108, 573–582 (2002). 
20. Kaufman, R. J. et al. The unfolded protein response in nutrient sensing and 
differentiation. Nat. Rev. Mol. Cell Biol. 3, 411–421 (2002). 
21. Stefani, M. Protein misfolding and aggregation: New examples in medicine and 
biology of the dark side of the protein world. Biochim. Biophys. Acta - Mol. Basis Dis. 
101 
 
1739, 5–25 (2004). 
22. Luheshi, L. M. & Dobson, C. M. Bridging the gap: From protein misfolding to protein 
misfolding diseases. FEBS Lett. 583, 2581–2586 (2009). 
23. Thomas, P. J., Qu, B. H. & Pedersen, P. L. Defective protein folding as a basis of human 
disease. Trends Biochem. Sci. 20, 456–459 (1995). 
24. Ellis, R. J. Macromolecular crowding: an important but neglected aspect of the 
intracellular environment. Curr. Opin. Struct. Biol. 11, 114–119 (2001). 
25. Priya, S., Sharma, S. K. & Goloubinoff, P. Molecular chaperones as enzymes that 
catalytically unfold misfolded polypeptides. FEBS Lett. 587, 1981–1987 (2013). 
26. Uversky, V. N. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 
277, 2940–2953 (2010). 
27. Makin, O. S. & Serpell, L. C. Structures for amyloid fibrils. FEBS J. 272, 5950–5961 
(2005). 
28. Baldwin, A. J. et al. Metastability of Native Proteins and the Phenomenon of Amyloid 
Formation. J. Am. Chem. Soc. 133, 14160–14163 (2011). 
29. Eanes, E. D. & Glenner, G. G. X-ray Diffraction Studies on Amyloid Filaments. J. 
Histochem. Cytochem. 16, 673–677 (1968). 
30. Marshall, K. E. & Serpell, L. C. Insights into the structure of amyloid fibrils. Open Biol. 
J. 2, 185–192 (2009). 
31. Ladiwala, A. R. A. et al. Conformational Differences between Two Amyloid β 
Oligomers of Similar Size and Dissimilar Toxicity. (2012). 
32. Bouchard, M., Zurdo, J., Nettleton, E. J., Dobson, C. M. & Robinson, C. V. Formation 
of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron 
microscopy. Protein Sci. 9, 1960–1967 (2000). 
33. Groenning, M. et al. Binding mode of Thioflavin T in insulin amyloid fibrils. J. Struct. 
Biol. 159, 483–497 (2007). 
34. Lührs, T. et al. 3D structure of Alzheimer’s amyloid-β(1–42) fibrils. Proc. Natl. Acad. 
Sci. 102, 17342–17347 (2005). 
35. Serpell, L. C. et al. The Protofilament Substructure of Amyloid Fibrils. 1033–1039 
(2000). doi:10.1006/jmbi.2000.3908 
36. Jiménez, J. L. et al. The protofilament structure of insulin amyloid fibrils. Proc. Natl. 
Acad. Sci. U. S. A. 99, 9196–201 (2002). 
37. Petkova, A. T. et al. A structural model for Alzheimer’s beta -amyloid fibrils based on 
experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 99, 
16742–7 (2002). 
38. Ma, B. & Nussinov, R. Stabilities and conformations of Alzheimer’s beta -amyloid 
peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects. 
Proc. Natl. Acad. Sci. U. S. A. 99, 14126–31 (2002). 
39. Sawaya, M. R. et al. Atomic structures of amyloid cross-β spines reveal varied steric 
zippers. Nature 447, 453 (2007). 
40. Soriaga, A. B., Sangwan, S., MacDonald, R., Sawaya, M. R. & Eisenberg, D. Crystal 
structures of IAPP amyloidogenic segments reveal a novel packing motif of out-of-
register beta sheets. J. Phys. Chem. B 120, 5810–5816 (2016). 
41. Rochet, J. C. & Lansbury, P. T. Amyloid fibrillogenesis: themes and variations. Curr. 
Opin. Struct. Biol. 10, 60–8 (2000). 
42. Khurana, R. et al. Mechanism of thioflavin T binding to amyloid fibrils. 151, 229–238 
(2005). 
43. Di Carlo, M. G. et al. Thioflavin T templates amyloid β(1-40) conformation and 
102 
 
aggregation pathway. Biophys. Chem. 206, 1–11 (2015). 
44. Xue, C., Lin, T. Y., Chang, D. & Guo, Z. Thioflavin T as an amyloid dye: Fibril 
quantification, optimal concentration and effect on aggregation. R. Soc. Open Sci. 4, 
(2017). 
45. Stsiapura, V. I., Maskevich, A. A., Kuzmitsky, V. A., Turoverov, K. K. & Kuznetsova, I. 
M. Computational Study of Thioflavin T Torsional Relaxation in the Excited State. J. 
Phys. Chem. A 111, 4829–4835 (2007). 
46. Voropai, E. S. et al. Spectral properties of thioflavin T and its complexes with amyloid 
fibrils. J. Appl. Spectrosc. 70, 868–874 (2003). 
47. Srivastava, A. et al. Identifying the Bond Responsible for the Fluorescence 
Modulation in an Amyloid Fibril Sensor. Chem. - A Eur. J. 16, 9257–9263 (2010). 
48. Ban, T., Hamada, D., Hasegawall, K., Naiki, H. & Goto, Y. Direct observation of 
amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 278, 
16462–16465 (2003). 
49. Naiki, H., Higuchi, K., Hosokawa, M. & Takeda, T. Fluorometric determination of 
amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Anal. Biochem. 177, 
244–249 (1989). 
50. Cohen, S. I. A. A. et al. Nucleated polymerization with secondary pathways. I. Time 
evolution of the principal moments. J. Chem. Phys. 135, 065105 (2011). 
51. Butterfield, S. M. & Lashuel, H. A. Amyloidogenic Protein–Membrane Interactions: 
Mechanistic Insight from Model Systems. Angew. Chemie Int. Ed. 49, 5628–5654 
52. Jahn, T. R. & Radford, S. E. The Yin and Yang of protein folding. FEBS J. 272, 5962–
5970 (2005). 
53. Dumoulin, M., Kumita, J. R. & Dobson, C. M. Normal and aberrant biological self-
assembly: Insights from studies of human lysozyme and its amyloidogenic variants. 
Acc. Chem. Res. 39, 603–610 (2006). 
54. Debelouchina, G. T., Platt, G. W., Bayro, M. J., Radford, S. E. & Griffin, R. G. Magic 
angle spinning NMR analysis of β 2-microglobulin amyloid fibrils in two distinct 
morphologies. J. Am. Chem. Soc. 132, 10414–10423 (2010). 
55. Uversky, V. N., Li, J. & Fink, A. L. Evidence for a Partially Folded Intermediate in ??-
Synuclein Fibril Formation. J. Biol. Chem. 276, 10737–10744 (2001). 
56. Calamai, M., Chiti, F. & Dobson, C. M. Amyloid fibril formation can proceed from 
different conformations of a partially unfolded protein. Biophys. J. 89, 4201–4210 
(2005). 
57. Bader, R., Bamford, R., Zurdo, J., Luisi, B. F. & Dobson, C. M. Probing the Mechanism 
of Amyloidogenesis through a Tandem Repeat of the PI3-SH3 Domain Suggests a 
Generic Model for Protein Aggregation and Fibril Formation. J. Mol. Biol. 356, 189–
208 (2006). 
58. Relini, A. et al. Monitoring the Process of HypF Fibrillization and Liposome 
Permeabilization by Protofibrils. J. Mol. Biol. 338, 943–957 (2004). 
59. Wilson, M. R., Yerbury, J. J. & Poon, S. Potential roles of abundant extracellular 
chaperones in the control of amyloid formation and toxicity. Mol. Biosyst. 4, 42–52 
(2007). 
60. Jansen, R., Dzwolak, W. & Winter, R. Amyloidogenic self-assembly of insulin 
aggregates probed by high resolution atomic force microscopy. Biophys. J. 88, 1344–
1353 (2005). 
61. Mielke, M. M., Vemuri, P. & Rocca, W. A. Clinical epidemiology of Alzheimer’s 
disease: Assessing sex and gender differences. Clin. Epidemiol. 6, 37–48 (2014). 
103 
 
62. Du, X., Wang, X. & Geng, M. Alzheimer’s disease hypothesis and related therapies. 
Transl. Neurodegener. 7, 1–7 (2018). 
63. Harris, J. R. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid 
Disease. (Springer Netherlands, 2012). at 
<https://books.google.it/books?id=R9upBYWAumgC> 
64. Hardy, J. & Selkoe, D. J. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress 
and Problems on the Road to Therapeutics. 
65. Karran, E., Mercken, M. & Strooper, B. De. The amyloid cascade hypothesis for 
Alzheimer’s disease: An appraisal for the development of therapeutics. Nat. Rev. 
Drug Discov. 10, 698–712 (2011). 
66. Dong, S., Duan, Y., Hu, Y. & Zhao, Z. Advances in the pathogenesis of Alzheimer’s 
disease: a re-evaluation of amyloid cascade hypothesis. Transl. Neurodegener. 1, 18 
(2012). 
67. Gong, Y. et al. Alzheimer’s disease-affected brain: Presence of oligomeric A  ligands 
(ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. 
100, 10417–10422 (2003). 
68. Chafekar, S. M., Hoozemans, J. J. M., Zwart, R., Baas, F. & Scheper, W. A β 1-42 Induces 
Mild Endoplasmic Reticulum Stress in an Aggregation State–Dependent Manner. 
Antioxid. Redox Signal. 9, 2245–2254 (2007). 
69. Journals, H. & Article, R. Alzheimer ’ s Disease : A Review. (2017). 
70. Eikelenboom, P. et al. Neuroinflammation in Alzheimer’s disease and prion disease. 
Glia 40, 232–239 (2002). 
71. Tan, S. Y. & Pepys, M. B. Amyloidosis. Histopathology 25, 403–14 (1994). 
72. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F. & Formigli, L. Inherent toxicity of 
aggregates implies a common mechanism for protein misfolding diseases. 507–511 
(2002). 
73. Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. 
Natl. Acad. Sci. 108, 4194–4199 (2011). 
74. Canale, C. et al. Different effects of Alzheimer’s peptide Aβ(1-40) oligomers and 
fibrils on supported lipid membranes. Biophys. Chem. 182, 23–29 (2013). 
75. Williams, T. L. & Serpell, L. C. Membrane and surface interactions of Alzheimer’s A?? 
peptide - Insights into the mechanism of cytotoxicity. FEBS J. 278, 3905–3917 (2011). 
76. Davis, C. H. & Berkowitz, M. L. Interaction between amyloid-β (1-42) peptide and 
phospholipid bilayers: A molecular dynamics study. Biophys. J. 96, 785–797 (2009). 
77. Seghezza, S., Diaspro, A., Canale, C. & Dante, S. Cholesterol drives Aβ(1-42) 
interaction with lipid rafts in model membranes. Langmuir 30, 13934–13941 (2014). 
78. Oropesa-Nuñez, R. et al. Interaction of toxic and non-toxic HypF-N oligomers with 
lipid bilayers investigated at high resolution with atomic force microscopy. 
Oncotarget 7, 44991–45004 (2016). 
79. Dante, S., Hauß, T. & Dencher, N. A. Cholesterol inhibits the insertion of the 
Alzheimer’s peptide Aβ(25-35) in lipid bilayers. Eur. Biophys. J. 35, 523–531 (2006). 
80. Williams, T. L. et al. Aβ42 oligomers, but not fibrils, simultaneously bind to and cause 
damage to ganglioside-containing lipid membranes. Biochem. J. 439, 67–77 (2011). 
81. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent 
central nervous system neurotoxins. Proc. Natl. Acad. Sci. 95, 6448–6453 (1998). 
82. Picone, P. et al. Biological and biophysics aspects of metformin-induced effects: 
Cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar 
aggregates. Aging (Albany. NY). 8, 1718–1734 (2016). 
104 
 
83. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared 
property of both alpha -synuclein mutations linked to early-onset Parkinson’s 
disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. 97, 571–
576 (2000). 
84. Cajavec, B. & Bernard, S. Aggregation in Huntington’s Disease. Genome Informatics 
16, 262–271 (2005). 
85. Hicks, D. A., Nalivaeva, N. N. & Turner, A. J. Lipid rafts and Alzheimer’s disease: 
Protein-lipid interactions and perturbation of signaling. Front. Physiol. 3 JUN, (2012). 
86. Wolozin, B. A fluid connection: cholesterol and Abeta. Proc. Natl. Acad. Sci. U. S. A. 
98, 5371–3 (2001). 
87. Esch, F. S. et al. Cleavage of amyloid β peptide during constitutive processing of its 
precursor. Science (80-. ). 248, 1122–1124 (1990). 
88. Seubert, P. et al. Secretion of β-amyloid precursor protein cleaved at the amino 
terminus of the β-amyloid peptide. Nature 361, 260 (1993). 
89. Galván, Y., Mori, H., Takio, K., Ogawara, M. & Selkoe, D. J. Mass spectrometry of 
purified amyloid beta protein in Alzheimer’s disease. J. Biol. Chem. 267, 17082–
17086 (1992). 
90. Naslund, J. et al. Relative abundance of Alzheimer A beta amyloid peptide variants 
in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. 91, 8378–8382 (1994). 
91. Meisl, G. et al. Differences in nucleation behavior underlie the contrasting 
aggregation kinetics of the Aβ40 and Aβ42 peptides. Proc. Natl. Acad. Sci. 111, 9384–
9389 (2014). 
92. Kodali, R. & Wetzel, R. Polymorphism in the intermediates and products of amyloid 
assembly. Curr. Opin. Struct. Biol. 17, 48–57 (2007). 
93. Schmidt, M. et al. Comparison of Alzheimer Aβ(1–40) and Aβ(1–42) amyloid fibrils 
reveals similar protofilament structures. Proc. Natl. Acad. Sci. 106, 19813 LP-19818 
(2009). 
94. Esbjörner, E. K. et al. Direct observations of amyloid β Self-assembly in live cells 
provide insights into differences in the kinetics of Aβ(1-40) and Aβ(1-42) 
aggregation. Chem. Biol. 21, 732–742 (2014). 
95. Cohen, S. I. A. et al. Proliferation of amyloid-β42 aggregates occurs through a 
secondary nucleation mechanism. Proc. Natl. Acad. Sci. U. S. A. 110, 9758–63 (2013). 
96. Sunde, M. et al. Common Core Structure of Amyloid Fibrils by Synchrotron X-ray 
Diffraction. (1997). 
97. Dobson, C. M. The structural basis of protein folding and its links with human 
disease. Philos. Trans. R. Soc. London. Ser. B Biol. Sci. 356, 133 LP-145 (2001). 
98. Chiti, F. et al. Designing conditions for in vitro formation of amyloid protofilaments 
and fibrils. Proc. Natl. Acad. Sci. 96, 3590–3594 (1999). 
99. Navarra, G. et al. Heat- and pH-induced BSA conformational changes, hydrogel 
formation and application as 3D cell scaffold. Arch. Biochem. Biophys. 606, 134–142 
(2016). 
100. Guijarro, J. I., Sunde, M., Jones, J. A., Campbell, I. D. & Dobson, C. M. Amyloid fibril 
formation by an SH3 domain. Proc. Natl. Acad. Sci. 95, 4224–4228 (1998). 
101. Litvinovich, S. V et al. Formation of amyloid-like fibrils by self-association of a 
partially unfolded fibronectin type III module11Edited by R. Huber. J. Mol. Biol. 280, 
245–258 (1998). 
102. Giovanna, M. et al. Trifluoroethanol modulates α-synuclein amyloid-like aggregate 
formation, stability and dissolution. Biophys. Chem. 216, 23–30 (2016). 
105 
 
103. Santangelo, M. G., Militello, V., Foderà, V. & Vetri, V. Back to the oligomeric state: 
pH-induced dissolution of concanavalin A amyloid-like fibrils into non-native 
oligomers. Rsc Adv. 6, 75082–75091 (2016). 
104. SUNDE, M. & BLAKE, C. in Advances in Protein Chemistry Volume 50 50, 123–159 
(Elsevier, 1997). 
105. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 
329–332 (1999). 
106. Zewail, A. H. Physical biology: from atoms to medicine. (Imperial college press, 2008). 
107. Paz, D. et al. De novo designed peptide-based amyloid fibrils. (2002). 
108. Broome, B. M. & Hecht, M. H. Nature Disfavors Sequences of Alternating Polar and 
Non-polar Amino Acids : Implications for Amyloidogenesis. 961–968 (2000). 
doi:10.1006/jmbi.2000.3514 
109. Brange, J. & Langkjœr, L. in Stability and Characterization of Protein and Peptide 
Drugs 315–350 (Springer, 1993). 
110. Brange, J., Andersen, L., Laursen, E. D., Meyn, G. & Rasmussen, E. Toward 
Understanding Insulin Fibrillation. J. Pharm. Sci. 86, 517–525 (1997). 
111. F. Sanger. F. Sanger, Biochem. J., 39 (1945) 507. 39, (1944). 
112. Ryle, A. P., Sanger, F., Smith, L. F. & Kitai, R. The disulphide bonds of insulin. Biochem. 
J. 60, 541–556 (1955). 
113. Tah, B. et al. Quantum-mechanical DFT calculation supported Raman spectroscopic 
study of some amino acids in bovine insulin. Spectrochim. Acta - Part A Mol. Biomol. 
Spectrosc. 129, 345–351 (2014). 
114. Brogden, R. N. & Heel, R. C. Human insulin. Drugs 34, 350–371 (1987). 
115. Heinemann, L., Heise, T., Jorgensen, L. N. & Starke, A. A. R. Action Profile of the Rapid 
Acting Insulin Analogue: Human Insulin B28Asp. Diabet. Med. 10, 535–539 
116. Chien, Y. W. Human Insulin: Basic Sciences to Therapeutic Uses. Drug Dev. Ind. 
Pharm. 22, 753–789 (1996). 
117. Dische, F. E. et al. Insulin as an amyloid-fibril protein at sites of repeated insulin 
injections in a diabetic patient. Diabetologia 31, 158–161 (1988). 
118. Brange, J. Galenics of insulin: the physico-chemical and pharmaceutical aspects of 
insulin and insulin preparations. (Springer Science & Business Media, 2012). 
119. Chiti, F. et al. Designing conditions for in vitro formation of amyloid protofilaments 
and fibrils. Proc. Natl. Acad. Sci. 96, 3590–3594 (1999). 
120. Relini, A. et al. Monitoring the process of HypF fibrillization and liposome 
permeabilization by protofibrils. J. Mol. Biol. 338, 943–957 (2004). 
121. Vetri, V. et al. Amyloid fibrils formation and amorphous aggregation in concanavalin 
A. Biophys. Chem. 125, 184–190 (2007). 
122. Nielsen, L., Frokjaer, S., Brange, J., Uversky, V. N. & Fink, A. L. Probing the Mechanism 
of Insulin Fibril Formation with Insulin Mutants. Biochemistry 40, 8397–8409 (2001). 
123. Burke, M. J. & Rougvie, M. A. Cross-β protein structures. I. Insulin fibrils. Biochemistry 
11, 2435–2439 (1972). 
124. Nielsen, L. et al. Effect of Environmental Factors on the Kinetics of Insulin Fibril 
Formation: Elucidation of the Molecular Mechanism. Biochemistry 40, 6036–6046 
(2001). 
125. Klunk, W. E., Pettergrew, J. W. & Abraham, D. J. Quatitative Evaluation of Congo Red 
Binding with a Beta-pleated to. J. Histochem. Cytochem. 37, 1273–1281 (1989). 
126. Smith, M. I., Sharp, J. S. & Roberts, C. J. Nucleation and growth of insulin fibrils in 




127. Knowles, T. P. J. et al. Kinetics and thermodynamics of amyloid formation from direct 
measurements of fluctuations in fibril mass. Proc. Natl. Acad. Sci. 104, 10016–10021 
(2007). 
128. Foderà, V., Librizzi, F., Groenning, M., Van De Weert, M. & Leone, M. Secondary 
nucleation and accessible surface in insulin amyloid fibril formation. J. Phys. Chem. 
B 112, 3853–3858 (2008). 
129. Librizzi, F., Foderà, V., Vetri, V., Lo Presti, C. & Leone, M. Effects of confinement on 
insulin amyloid fibrils formation. Eur. Biophys. J. 36, 711–715 (2007). 
130. Nayak, A., Sorci, M., Krueger, S. & Belfort, G. A universal pathway for amyloid nucleus 
and precursor formation for insulin. Proteins Struct. Funct. Bioinforma. 74, 556–565 
(2009). 
131. Vestergaard, B. et al. A Helical Structural Nucleus Is the Primary Elongating Unit of 
Insulin Amyloid Fibrils. PLoS Biol. 5, e134 (2007). 
132. van Maarschalkerweerd, A., Vetri, V., Langkilde, A. E., Foderà, V. & Vestergaard, B. 
Protein/Lipid Coaggregates are Formed During α-Synuclein-Induced Disruption of 
Lipid Bilayers. Biomacromolecules 15, 3643–3654 (2014). 
133. Yang, X., Askarova, S. & Lee, J. C. M. Membrane biophysics and mechanics in 
Alzheimer’s disease. Mol. Neurobiol. 41, 138–148 (2010). 
134. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent 
central nervous system neurotoxins. Proc. Natl. Acad. Sci. 95, 6448–6453 (1998). 
135. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared 
property of both α-synuclein mutations linked to early-onset Parkinson’s disease: 
implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. 97, 571–576 (2000). 
136. Nucifora, L. G. et al. Identification of novel potentially toxic oligomers formed in vitro 
from mammalian-derived expanded huntingtin exon-1 protein. J. Biol. Chem. 287, 
16017–16028 (2012). 
137. Kim, H.-Y. et al. Structural properties of pore-forming oligomers of α-synuclein. J. 
Am. Chem. Soc. 131, 17482–17489 (2009). 
138. Azimov, R. & Kagan, B. L. in Electrophysiology of Unconventional Channels and Pores 
(ed. Delcour, A. H.) 343–360 (Springer International Publishing, 2015). 
doi:10.1007/978-3-319-20149-8_14 
139. Lin, H. A. I., Bhatia, R. & Lal, R. Amyloid β protein forms ion channels: implications 
for Alzheimer’s disease pathophysiology. FASEB J. 15, 2433–2444 (2001). 
140. Zhu, D. et al. Role of membrane biophysics in Alzheimer’s-related cell pathways. 
Front. Neurosci. 9, 186 (2015). 
141. Domanov, Y. A. & Kinnunen, P. K. J. Islet amyloid polypeptide forms rigid lipid–
protein amyloid fibrils on supported phospholipid bilayers. J. Mol. Biol. 376, 42–54 
(2008). 
142. Kapitza, H. G. Microscopy from the very beginning. Carl Zeiss Oberkochen 1–48 
(1997). doi:10.1111/j.1750-8606.2012.00246.x 
143. Abbe, E. Beiträge zur Theorie des Mikroskops und der mikroskopischen 
Wahrnehmung. Arch. für mikroskopische Anat. 9, 413–418 (1873). 
144. Jablonski, A. Efficiency of anti-Stokes fluorescence in dyes. Nature 131, 839 (1933). 
145. Wilson, T., Shepparu, C. J. R. & Löschke, K. Theory and practice of scanning optical 
microscopy. Academic Press, London 1984, 213 Seiten, 138 Abbildungen, Preis $ 
39.50 ISBN 0-12-757760-2. Cryst. Res. Technol. 20, 1608–1608 (1985). 
146. Hell, S. W. & Wichmann, J. Breaking the diffraction resolution limit by stimulated 
107 
 
emission: stimulated-emission-depletion fluorescence microscopy. Opt. Lett. 19, 780 
(1994). 
147. Esplandiu, M. J. Scanning probe microscopies for analytical studies at the nanometer 
scale. 3, 33–46 (2005). 
148. Mellors, R. C. & Silver, R. A microfluorometric scanner for the differential detection 
of cells: Application to exfoliative cytology. Science (80-. ). 114, 356–360 (1951). 
149. Minsky, M. Microscopy apparatus US patent 3013467. USP Off. Ed. US (1961). 
150. Yeats, R. M., Yeats, M. F., Sheppard, C. J. R. & Wilson, T. The theory of the direct-
view confocal microscope. J. Microsc. 124, 107–117 (1981). 
151. Földes-Papp, Z., Demel, U. & Tilz, G. P. Laser scanning confocal fluorescence 
microscopy: An overview. Int. Immunopharmacol. 3, 1715–1729 (2003). 
152. Benda, A., Aitken, H., Davies, D. S., Whan, R. & Goldsbury, C. STED imaging of tau 
filaments in Alzheimer’s disease cortical grey matter. J. Struct. Biol. 195, 345–352 
(2016). 
153. Huang, B., Babcock, H. & Zhuang, X. Breaking the diffraction barrier: Super-
resolution imaging of cells. Cell 143, 1047–1058 (2010). 
154. Betzig E, Hell SW, Moerner WE (2014) The Nobel Prize in Chemistry 2014. In: 
Nobelprize.org. http://www.nobelprize.org/nobel_prizes/ 
chemistry/laureates/2014/. Accessed 24 Jan 2015. 
155. Dickson, R. M., Cubitt, A. B., Tsien, R. Y. & Moerner, W. E. On/off blinking and 
switching behaviour of single molecules of green fluorescent protein. Nature 388, 
355–358 (1997). 
156. Betzig, E. et al. Imaging Intracellular Fluorescent Proteins at Nanometer Resolution. 
Science (80-. ). 313, 1642–1645 (2006). 
157. Mahou, P., Curry, N., Pinotsi, D., Schierle, K. & Clemens, F. Simulated Emission 
Depletion microscopy to study amyloid fibril formation. 9331, 1–10 (2015). 
158. Jensen, E. & Crossman, D. J. Technical review: Types of imaging-direct STORM. Anat. 
Rec. 297, 2227–2231 (2014). 
159. Chacko, J. V., Zanacchi, F. C. & Diaspro, A. Probing cytoskeletal structures by coupling 
optical superresolution and AFM techniques for a correlative approach. Cytoskeleton 
70, 729–740 (2013). 
160. Van De Linde, S. et al. Direct stochastic optical reconstruction microscopy with 
standard fluorescent probes. Nat. Protoc. 6, 991–1009 (2011). 
161. Lee, S.-H., Shin, J. Y., Lee, A. & Bustamante, C. Counting single photoactivatable 
fluorescent molecules by photoactivated localization microscopy (PALM). Proc. Natl. 
Acad. Sci. (2012). 
162. Hell, S. W., Dyba, M. & Jakobs, S. Concepts for nanoscale resolution in fluorescence 
microscopy. Curr. Opin. Neurobiol. 14, 599–609 (2004). 
163. Gustafsson, M. G. L. Surpassing the lateral resolution limit by a factor of two using 
structured illumination microscopy. J. Microsc. 198, 82–87 (2000). 
164. Heintzmann, R. & Cremer, C. G. Laterally modulated excitation microscopy: 
improvement of resolution by using a diffraction grating. in Optical Biopsies and 
Microscopic Techniques III 3568, 185–197 (International Society for Optics and 
Photonics, 1999). 
165. Hell, S. W. et al. The 2015 super-resolution microscopy roadmap. J. Phys. D. Appl. 
Phys. 48, (2015). 
166. Vicidomini, G. et al. Gated CW-STED microscopy: A versatile tool for biological 
nanometer scale investigation. Methods 66, 124–130 (2014). 
108 
 
167. Lichtman, J. W. & Conchello, J.-A. Fluorescence microscopy. Nat. Methods 2, 910 
(2005). 
168. Diaspro, A., Chirico, G., Usai, C., Ramoino, P. & Dobrucki, J. Photobleaching. Handb. 
Biol. Confocal Microsc. 690–702 (2006). doi:doi: 10.1007/978-0-387-45524-2_39 
169. Hell, S. W. Toward fluorescence nanoscopy. Nat. Biotechnol. 21, 1347–1355 (2003). 
170. Willig, K. I., Harke, B., Medda, R. & Hell, S. W. STED microscopy with continuous wave 
beams. Nat. Methods 4, 915–918 (2007). 
171. Vicidomini, G. et al. Sharper low-power STED nanoscopy by time gating. Nat. 
Methods 8, 571–575 (2011). 
172. Binnig, G., Rohrer, H., Gerber, C. & Weibel, E. Surface Studies by Scanning Tunneling 
Microscopy. Phys. Rev. Lett. 49, 57–61 (1982). 
173. Binnig, G., Quate, C. F. & Gerber, C. Atomic Force Microscope. Phys. Rev. Lett. 56, 
930–933 (1986). 
174. Moreno-Flores, S. & Toca-Herrera, J. L. Hybridizing surface probe microscopies: 
Toward a full description of the meso-and nanoworlds. (CRC Press, 2012). 
175. Meyer, G. & Amer, N. M. Novel optical approach to atomic force microscopy. Appl. 
Phys. Lett. 53, 1045–1047 (1988). 
176. Meyer, G. & Amer, N. M. Novel optical approach to atomic force microscopy [Appl. 
Phys. Lett. 5 3, 1045 (1988)]. Appl. Phys. Lett. 53, 2400–2402 (1988). 
177. Hutter, J. L., Bechhoefer, J., Hutter, J. L. & Bechhoefer, J. Calibration of atomicforce 
microscope tips microscope tips. 1868, (2012). 
178. Park, S., Costa, K. D. & Ateshian, G. A. Microscale frictional response of bovine 
articular cartilage from atomic force microscopy. J. Biomech. 37, 1679–1687 (2004). 
179. Martínez, N. F. & García, R. Measuring phase shifts and energy dissipation with 
amplitude modulation atomic force microscopy. Nanotechnology 17, S167 (2006). 
180. Melcher, J. et al. Origins of phase contrast in the atomic force microscope in liquids. 
Proc. Natl. Acad. Sci. 106, 13655–13660 (2009). 
181. Cappella, B. & Dietler, G. Force-distance curves by atomic force microscopy. Surf. Sci. 
Rep. 34, 1–104 (1999). 
182. Bizzarri, A. R. & Cannistraro, S. The application of atomic force spectroscopy to the 
study of biological complexes undergoing a biorecognition process. Chem. Soc. Rev. 
39, 734–749 (2010). 
183. Zlatanova, J., Lindsay, S. M. & Leuba, S. H. Single molecule force spectroscopy in 
biology using the atomic force microscope. Prog. Biophys. Mol. Biol. 74, 37–61 
(2000). 
184. Krotil, H. et al. Pulsed force mode: a new method for the investigation of surface 
properties. Surf. Interface Anal. 27, 336–340 (1999). 
185. Diaspro, A. & van Zandvoort, M. A. M. J. Super-resolution Imaging in Biomedicine. 
(CRC press, 2016). 
186. Dufrêne, Y. F. et al. Imaging modes of atomic force microscopy for application in 
molecular and cell biology. Nat. Nanotechnol. 12, 295–307 (2017). 
187. Kronlage, C., Schäfer-Herte, M., Böning, D., Oberleithner, H. & Fels, J. Feeling for 
Filaments: Quantification of the Cortical Actin Web in Live Vascular Endothelium. 
Biophys. J. 109, 687–698 (2015). 
188. Moreno Flores, S. & Toca-Herrera, J. L. The new future of scanning probe 
microscopy: Combining atomic force microscopy with other surface-sensitive 




189. Brown, A. E. X., Hategan, A., Safer, D., Goldman, Y. E. & Discher, D. E. Cross-
correlated TIRF/AFM reveals asymmetric distribution of force-generating heads 
along self-assembled, ‘synthetic’ myosin filaments. Biophys. J. 96, 1952–1960 (2009). 
190. Harke, B., Chacko, J. V., Haschke, H., Canale, C. & Diaspro, A. A novel nanoscopic tool 
by combining AFM with STED microscopy. Opt. Nanoscopy 1, 1–6 (2012). 
191. Chacko, J. V., Canale, C., Harke, B. & Diaspro, A. Sub-Diffraction Nano Manipulation 
Using STED AFM. PLoS One 8, (2013). 
192. Chacko, J. V., Harke, B., Canale, C. & Diaspro, A. Cellular level nanomanipulation 
using atomic force microscope aided with superresolution imaging. J. Biomed. Opt. 
19, 105003 (2014). 
193. Whittingham, J. L. et al. Insulin at pH 2: Structural analysis of the conditions 
promoting insulin fibre formation. J. Mol. Biol. 318, 479–490 (2002). 
194. Snyder, S. W. et al. Amyloid-beta aggregation: selective inhibition of aggregation in 
mixtures of amyloid with different chain lengths. Biophys. J. 67, 1216–1228 (1994). 
195. Gaetano, S. Di et al. Recombinant amyloidogenic domain of ApoA-I: Analysis of its 
fibrillogenic potential. Biochem. Biophys. Res. Commun. 351, 223–228 (2006). 
196. Carrotta, R. et al. Inhibiting effect of αs1-casein on Aβ1–40 fibrillogenesis. Biochim. 
Biophys. Acta - Gen. Subj. 1820, 124–132 (2012). 
197. Bianchini, P. et al. STED nanoscopy: a glimpse into the future. Cell Tissue Res. 360, 
143–150 (2015). 
198. Bolte, S. & Cordelières, F. P. A guided tour into subcellular colocalization analysis in 
light microscopy. J. Microsc. 224, 213–32 (2006). 
199. Manders, E. M. M., Verbeek, F. J. & Aten, J. A. Measurement of co-localization of 
objects in dual-colour confocal images. J. Microsc. 169, 375–382 (1993). 
200. Costes, S. V. et al. Automatic and quantitative measurement of protein-protein 
colocalization in live cells. Biophys. J. 86, 3993–4003 (2004). 
201. D’Amico, M. et al. Thioflavin T promotes Aβ (1–40) amyloid fibrils formation. J. Phys. 
Chem. Lett. 3, 1596–1601 (2012). 
202. Manno, M. et al. Kinetics of Different Processes in Human Insulin Amyloid 
Formation. J. Mol. Biol. 366, 258–274 (2007). 
203. Xue, W.-F., Homans, S. W. & Radford, S. E. Systematic analysis of nucleation-
dependent polymerization reveals new insights into the mechanism of amyloid self-
assembly. Proc. Natl. Acad. Sci. 105, 8926–8931 (2008). 
204. Mangione, M. R. et al. Hsp60, amateur chaperone in amyloid-beta fibrillogenesis. 
Biochim. Biophys. Acta - Gen. Subj. 1860, 2474–2483 (2016). 
205. Calamai, M. et al. Reversal of Protein Aggregation Provides Evidence for Multiple 
Aggregated States. J. Mol. Biol. 346, 603–616 (2005). 
206. Kad, N. M. et al. Hierarchical Assembly of β2-Microglobulin Amyloid In Vitro 
Revealed by Atomic Force Microscopy. J. Mol. Biol. 330, 785–797 (2003). 
207. Morris, V. J., Kirby, A. R. & Gunning, A. P. Atomic force microscopy for biologists. 
(World Scientific, 1999). 
208. Mahou, P. et al. Stimulated emission depletion microscopy to study amyloid fibril 
formation. Proc. SPIE 9331, 93310U (2015). 
209. Kaminski Schierle, G. S., Sauer, M. & Kaminski, C. F. Probing Amyloid Aggregation and 
Morphology In Situ by Multiparameter Imaging and Super-Resolution Fluorescence 
Microscopy. Bio-nanoimaging Protein Misfolding Aggreg. 105–120 (2013). 
doi:10.1016/B978-0-12-394431-3.00010-9 
210. Kaminski, C. F., Pinotsi, D., Michel, C. H. & Schierle, G. S. K. Nanoscale imaging of 
110 
 
neurotoxic proteins. SPIE Nanosci. Eng. 9169, 91690N----91690N (2014). 
211. Fornasiero, E. F. & Opazo, F. Super-resolution imaging for cell biologists. BioEssays 
37, 436–451 (2015). 
212. Apetri, M. M. et al. Direct observation of α-synuclein amyloid aggregates in 
endocytic vesicles of neuroblastoma cells. PLoS One 11, 1–13 (2016). 
213. Luitz, M. P. et al. Covalent dye attachment influences the dynamics and 
conformational properties of flexible peptides. PLoS One 12, 1–18 (2017). 
214. Hartmann, A., Krainer, G. & Schlierf, M. Different fluorophore labeling strategies and 
designs affect millisecond kinetics of DNA hairpins. Molecules 19, 13735–13754 
(2014). 
215. van Ham, T. J. et al. Towards Multiparametric Fluorescent Imaging of Amyloid 
Formation: Studies of a YFP Model of α-Synuclein Aggregation. J. Mol. Biol. 395, 627–
642 (2010). 
216. ATTO-TEC. Fluorescent Labels and Dyes. Fluoresc. Labels Dye. Cat. 49, 1–45 (2007). 
217. Kaminski Schierle, G. S. et al. In Situ Measurements of the Formation and 
Morphology of Intracellular β-Amyloid Fibrils by Super-Resolution Fluorescence 
Imaging. J. Am. Chem. Soc. 133, 12902–12905 (2011). 
218. Braga, P. C. & Ricci, D. Atomic force microscopy: biomedical methods and 
applications. 242, (Springer Science & Business Media, 2004). 
219. Raposo, M., Ferreira, Q. & Ribeiro, P. A Guide for Atomic Force Microscopy Analysis 
of Soft Condensed Matter. Mod. Res. Educ. Top. Microsc. 1, (2007). 
220. Braga, P. C. & Ricci, D. Atomic force microscopy in biomedical research: methods and 
protocols. (Springer, 2011). 
221. Bolder, S. G., Sagis, L. M. C., Venema, P. & Van Linden, E. Der. Thioflavin T and 
birefringence assays to determine the conversion of proteins into fibrils. Langmuir 
23, 4144–4147 (2007). 
222. Chan, F. T. S., Pinotsi, D., Kaminski Schierle, G. S. & Kaminski, C. F. Structure-Specific 
Intrinsic Fluorescence of Protein Amyloids Used to Study their Kinetics of 
Aggregation. Bio-nanoimaging: Protein Misfolding and Aggregation (Elsevier, 2013). 
doi:10.1016/B978-0-12-394431-3.00013-4 
223. Canale, C., Relini, A. & Gliozzi, A. in Atomic Force Microscopy in Biomedical Research: 
Methods and Protocols (eds. Braga, P. C. & Ricci, D.) 81–95 (Humana Press, 2011). 
doi:10.1007/978-1-61779-105-5_6 
224. Gremer, L. et al. Fibril structure of amyloid- b (1 – 42) by cryo – electron microscopy. 
119, 116–119 (2017). 
225. Young, L. J., Kaminski Schierle, G. S. & Kaminski, C. F. Imaging Aβ(1–42) fibril 
elongation reveals strongly polarised growth and growth incompetent states. Phys. 
Chem. Chem. Phys. 19, 27987–27996 (2017). 
226. Schedin-Weiss, S., Caesar, I., Winblad, B., Blom, H. & Tjernberg, L. O. Super-
resolution microscopy reveals γ-secretase at both sides of the neuronal synapse. 
Acta Neuropathol. Commun. 4, 29 (2016). 
227. Ries, J. et al. Superresolution imaging of amyloid fibrils with binding-activated 
probes. ACS Chem. Neurosci. 4, 1057–1061 (2013). 
228. Pinotsi, D. et al. Direct observation of heterogeneous amyloid fibril growth kinetics 
via two-color super-resolution microscopy. Nano Lett. 14, 339–345 (2014). 
229. Ahn, M. et al. Analysis of the Native Structure, Stability and Aggregation of 
Biotinylated Human Lysozyme. PLoS One 7, (2012). 
230. Ahmed, S. Nanoscopy of cell architecture: The actin-membrane interface. 
111 
 
Bioarchitecture 1, 32–38 (2011). 
231. Young, L. J., Kaminski Schierle, G. S. & Kaminski, C. Imaging Aβ(1–42) fibril elongation 
reveals strongly polarised growth and growth incompetent states. Phys. Chem. 
Chem. Phys. 19, 27987–27996 (2017). 
232. Pinotsi, D. et al. kinetics via two-color super-resolution microscopy Direct 
observation of heterogeneous amyloid fibril growth kinetics via two-color super-
resolution microscopy. 1–9 (2013). 
233. Vestergaard, M. et al. Detection of Alzheimer ’ s amyloid beta aggregation by 
capturing molecular trails of individual assemblies. Biochem. Biophys. Res. Commun. 
377, 725–728 (2008). 
234. O`Brien JS, S. E. L. Lipid composition of the normal human brain. J. Lipid Res. 6, 537–
544 (1965). 
235. Ashrafuzzaman, M. & Tuszynski, J. A. Membrane biophysics. (Springer Science & 
Business Media, 2012). 
236. Kartal, A. et al. Analyses of the energy sources used by Turkish referees during ninety 
minutes soccer match. Life Sci. J. 10, 562–567 (2013). 
237. Boesze-battaglia, K. Cell membrane lipid composition and distribution : Implications 
for cell function and lessons learned from photoreceptors and platelets CELL 
MEMBRANE LIPID COMPOSITION AND DISTRIBUTION : IMPLICATIONS. 2936, 2927–
2936 (2016). 
238. Vance, J. E. & Vance, D. E. Biochemistry of lipids, lipoproteins and membranes. 
(Elsevier, 2008). 
239. Singer, S. J. & Nicolson, G. L. The Fluid Mosaic Model of the Structure of Cell 
Membranes. Science (80-. ). 175, 720 LP-731 (1972). 
240. Simons, K. & Ikonen, E. Functional rafts in cell membranes. Nature 387, 569–572 
(1997). 
241. Mayor, S. & Rao, M. Rafts: Scale-dependent, active lipid organization at the cell 
surface. Traffic 5, 231–240 (2004). 
242. Simons, K. & Meers, G. Perspectives in Biochemistry Lipid Sorting in Epithelial Cells. 
Biochem. Soc. Trans. 27, 6197–6202 (1988). 
243. London, E. & Brown, D. A. Insolubility of lipids in Triton X-100: Physical origin and 
relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim. 
Biophys. Acta - Biomembr. 1508, 182–195 (2000). 
244. Simons, K. & Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 
1, 31–9 (2000). 
245. Pike, L. J. Rafts defined: a report on the Keystone symposium on lipid rafts and cell 
function. J. Lipid Res. 47, 1597–1598 (2006). 
246. Lingwood, D. & Simons, K. Lipid Rafts As a Membrane-Organizing Principle. Science 
(80-. ). 327, 46 LP-50 (2010). 
247. Seghezza, S., Dante, S., Diaspro, A. & Canale, C. High resolution nanomechanical 
characterization of multi-domain model membranes by fast Force Volume. J. Mol. 
Recognit. 28, 742–750 (2015). 
248. Chiantia, S., Kahya, N., Ries, J. & Schwille, P. Effects of ceramide on liquid-ordered 
domains investigated by simultaneous AFM and FCS. Biophys. J. 90, 4500–4508 
(2006). 
249. Chiantia, S. et al. Role of ceramide in membrane protein organization investigated 




250. Schengrund, C.-L. Lipid rafts: keys to neurodegeneration. Brain Res. Bull. 82, 7–17 
(2010). 
251. BHATIA, R., LIN, H. A. I. & LAL, R. Fresh and globular amyloid β protein (1–42) induces 
rapid cellular degeneration: evidence for AβP channel-mediated cellular toxicity. 
FASEB J. 14, 1233–1243 (2000). 
252. Al-Habori, M. Macromolecular crowding and its role as intracellular signalling of cell 
volume regulation. Int. J. Biochem. Cell Biol. 33, 844–864 (2001). 
253. Nilsberth, C. et al. The’Arctic’APP mutation (E693G) causes Alzheimer’s disease by 
enhanced Aβ protofibril formation. Nat. Neurosci. 4, 887 (2001). 
254. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury Jr, P. T. 
Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 
291 (2002). 
255. Novelli, F. et al. Supporting information for : Intense THz reveals coupled protein-
hydration dielectric response in native and aggregated human lysozyme solutions. 
3–8 
256. Kourie, J. I. & Henry, C. L. Ion channel formation and membrane-linked pathologies 
of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. 
Clin. Exp. Pharmacol. Physiol. 29, 741–753 (2002). 
257. Hirakura, Y. & Kagan, B. L. Pore formation by beta-2-microglobulin: a mechanism for 
the pathogenesis of dialysis associated amyloidosis. Amyloid 8, 94–100 (2001). 
258. Volles, M. J. & Lansbury, P. T. Vesicle permeabilization by protofibrillar α-synuclein 
is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like 
mechanism. Biochemistry 41, 4595–4602 (2002). 
259. Dante, S., Hauß, T. & Dencher, N. A. Cholesterol inhibits the insertion of the 
Alzheimer’s peptide Aβ(25–35) in lipid bilayers. Eur. Biophys. J. 35, 523–531 (2006). 
260. Kayed, R. et al. Permeabilization of lipid bilayers is a common conformation-
dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. 
Biol. Chem. 279, 46363–46366 (2004). 
261. Durell, S. R., Guy, H. R., Arispe, N., Rojas, E. & Pollard, H. B. Theoretical models of the 
ion channel structure of amyloid beta-protein. Biophys. J. 67, 2137–2145 (1994). 
262. Kim, H. et al. Structural Properties of Pore-Forming Oligomers of α-Synuclein. J. Am. 
Chem. Soc. 131, 17482–17489 (2009). 
263. Kagan, B. L., Azimov, R. & Azimova, R. Amyloid peptide channels. J. Membr. Biol. 202, 
1–10 (2004). 
264. Chi, E. Y. et al. Amyloid-beta fibrillogenesis seeded by interface-induced peptide 
misfolding and self-assembly. Biophys. J. 98, 2299–2308 (2010). 
265. Okada, T., Ikeda, K., Wakabayashi, M., Ogawa, M. & Matsuzaki, K. Formation of Toxic 
Aβ(1-40) Fibrils on GM1 Ganglioside-Containing Membranes Mimicking Lipid Rafts: 
Polymorphisms in Aβ(1-40) Fibrils. J. Mol. Biol. 382, 1066–1074 (2008). 
266. Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W. & Strittmatter, S. M. Cellular 
prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. 
Nature 457, 1128 (2009). 
267. Renner, M. et al. Deleterious Effects of Amyloid β Oligomers Acting as an 
Extracellular Scaffold for mGluR5. Neuron 66, 739–754 (2010). 
268. Kremer, J. J., Pallitto, M. M., Sklansky, D. J. & Murphy, R. M. Correlation of β-Amyloid 
Aggregate Size and Hydrophobicity with Decreased Bilayer Fluidity of Model 
Membranes. Biochemistry 39, 10309–10318 (2000). 
269. Yip, C. M. & McLaurin, J. Amyloid-β peptide assembly: A critical step in fibrillogenesis 
113 
 
and membrane disruption. Biophys. J. 80, 1359–1371 (2001). 
270. Ambroggio, E. E. et al. Surface behavior and lipid interaction of Alzheimer β-amyloid 
peptide 1-42: A membrane-disrupting peptide. Biophys. J. 88, 2706–2713 (2005). 
271. Kawasaki, T. Structure and Function of Serum Mannan-binding Protein. Nippon 
Ishinkin Gakkai Zasshi 33, 105–112 (1992). 
272. Diao, J. et al. Native α-synuclein induces clustering of synaptic-vesicle mimics via 
binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2013, 1–17 (2013). 
273. Burré, J. The synaptic function of α-synuclein. J. Parkinsons. Dis. 5, 699–713 (2015). 
274. Ibáñez, P. et al. Causal relation between α-synuclein gene duplication and familial 
Parkinson’s disease. Lancet 364, 1169–1171 (2004). 
275. Ahn, B. H. et al. α-synuclein interacts with phospholipase D isozymes and inhibits 
pervanadate-induced phospholipase d activation in human embryonic kidney-293 
cells. J. Biol. Chem. 277, 12334–12342 (2002). 
276. Rodriguez, J. A. et al. Structure of the toxic core of α-synuclein from invisible crystals. 
Nature 525, 486 (2015). 
277. Rajagopalan, S. & Andersen, J. K. Alpha synuclein aggregation: Is it the toxic gain of 
function responsible for neurodegeneration in Parkinson’s disease? Mech. Ageing 
Dev. 122, 1499–1510 (2001). 
278. Ahn, M., Kim, S. B., Kang, M., Ryu, Y. & Doohun Kim, T. Chaperone-like activities of 
α-synuclein: α-Synuclein assists enzyme activities of esterases. Biochem. Biophys. 
Res. Commun. 346, 1142–1149 (2006). 
279. Hoyer, W. et al. Dependence of α-synuclein aggregate morphology on solution 
conditions. J. Mol. Biol. 322, 383–393 (2002). 
280. Gaspar, R., Pallbo, J., Weininger, U., Linse, S. & Sparr, E. Ganglioside lipids accelerate 
α-synuclein amyloid formation. Biochim. Biophys. Acta - Proteins Proteomics 1866, 
1062–1072 (2018). 
281. Crane, J. M., Kiessling, V. & Tamm, L. K. Measuring lipid asymmetry in planar 
supported bilayers by fluorescence interference contrast microscopy. Langmuir 21, 
1377–1388 (2005). 
282. Van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are 
and how they behave. Nat. Rev. Mol. cell Biol. 9, 112 (2008). 
283. Mingeot-Leclercq, M.-P., Deleu, M., Brasseur, R. & Dufrêne, Y. F. Atomic force 
microscopy of supported lipid bilayers. Nat. Protoc. 3, 1654 (2008). 
284. Milhiet, P. E., Giocondi, M.-C. & Le Grimellec, C. AFM imaging of lipid domains in 
model membranes. Sci. World J. 3, 59–74 (2003). 
285. Hane, F., Drolle, E., Gaikwad, R., Faught, E. & Leonenko, Z. Amyloid-β aggregation on 
model lipid membranes: An atomic force microscopy study. J. Alzheimer’s Dis. 26, 
485–494 (2011). 
286. Sheikh, K., Giordani, C., McManus, J. J., Hovgaard, M. B. & Jarvis, S. P. Differing modes 
of interaction between monomeric Aβ 1–40 peptides and model lipid membranes: 
An AFM study. Chem. Phys. Lipids 165, 142–150 (2012). 
287. Sennvik, K. A study of b-secretase cleaved Alzheimer amyloid precursor protein. 
(Institutionen för klinisk neurovetenskap, arbetsterapi och äldrevårdsforskning 
(NEUROTEC)/Department of Clinical Neuroscience, Occupational Therapy and 
Elderly Care Research (NEUROTEC), 2002). 
288. Ivanova, M. I., Sievers, S. A., Sawaya, M. R., Wall, J. S. & Eisenberg, D. Molecular basis 
for insulin fibril assembly. Proc. Natl. Acad. Sci. 106, 18990 LP-18995 (2009). 
289. JPK. NanoWizard ® AFM Handbook JPK Instruments NanoWizard ® Handbook 
114 
 
Version 2.2a 1. (2012). 
290. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury Jr, P. T. Amyloid pores 
from pathogenic mutations. Nature 418, 291 (2002). 
 
